Sequential epitope-specific antibodies for the diagnosis and clinical phenotyping of wheat allergy

Abstract

Peptide biomarkers, including methods and kits employing the same, for diagnosis of wheat allergy, and tolerance thereto, and for determining whether an allergic subject is likely to outgrow the allergy are presented herein.

Description

[0001]27527-0242WO1; ISMMS Ref.231101 Sequential Epitope-Specific Antibodies For The Diagnosis and Clinical Phenotyping Of Wheat Allergy Field The present disclosure is directed, in part, to peptide biomarkers, including methods and kits employing the same, for diagnosis of wheat allergy and for determining whether an allergic subject is likely to outgrow the allergy. Sequence Listing This application contains a Sequence Listing that has been submitted electronically as an XML file named 27527-0242WO1_SL_ST26.xml. The XML file, created on February 19, 2025, is 69,925 bytes in size. The material in the XML file is hereby incorporated by reference in its entirety. Background In recent years there has been a notable increase in the prevalence of food allergies worldwide (Spolidoro et al., Allergy, 2022; and Sampath et al., J. Allergy Clin. Immunol., 2021, 148, 1347-64). Of particular interest, wheat (Triticum spp.) has emerged as a significant dietary component globally and has gained recognition as one of the major food allergens responsible for allergic reactions (Turner et al., Allergy, 2022, 77, 2634-52; and Srisuwatchari et al., Asia Pac. Allergy, 2018; 8, e21). Wheat can elicit immune-mediated reactions categorized into two primary types: immunoglobulin (Ig)E-mediated and non-IgE-mediated responses. The clinical presentation of IgE-mediated wheat allergy can range from milder phenotypes characterized by isolated mucocutaneous manifestations, such as urticaria or angioedema, to the most severe form, anaphylaxis (Cianferoni, J. Asthma Allergy, 2016, 9, 13-25; and Srisuwatchari et al., Asian Pac. J. Allergy Immunol., 2022, 40, 263-8). In addition to classic IgE-mediated reactions, a unique clinical phenotype of food allergy known as wheat-dependent exercise-induced 27527-0242WO1; ISMMS Ref.231101 anaphylaxis (WDEIA) has also been reported (Kulthanan et al., J. Allergy Clin. Immunol. Pract., 2022, 10, 2280-96). The diagnosis of wheat allergy involves a detailed clinical history and in vivo or invitro tests, including skin prick tests (SPT), specific IgE (sIgE) assays, and, in some cases,component diagnostics, such as sIgE to omega-5 gliadin ( -5-g). However, unlike othercommon food allergens, these diagnostic tests for wheat allergy exhibit more limited diagnostic value (Srisuwatchari et al., Asian Pac. J. Allergy Immunol., 2022, 40, 263-8; Ebisawa et al., Int. Arch Allergy Immunol., 2012, 158, 71-6; Palosuo et al., J. Allergy Clin. Immunol., 2001, 108, 634-8; Sampson et al., J. Allergy Clin. Immunol., 2001, 107, 891-6; Graham et al., Int. Arch Allergy Immunol., 2020, 181, 296-300; Santos et al., Allergy, 2023, 78, 3057-76; and Riggioni et al., Allergy, 2023). Hence, achieving an accurate diagnosis is very challenging and utilization of an oral food challenge (OFC) is often necessary, which is time-consuming and involves significant risks (Santos et al., Allergy, 2023, 78, 3057-76). Major allergens in wheat protein can be classified into four groups: albumins (water-soluble), globulins (salt-soluble), gliadins (soluble in alcohol / water mixtures), and glutenins (soluble in diluted acid) (Mäkelä et al., Clin. Exp. Allergy, 2014, 44, 1420-30). Among these, -5-g has gained widespread recognition as a significant allergen. It is not only responsible for IgE-mediated wheat allergy but also plays a crucial role in WDEIA (Palosuo et al., J. Allergy Clin. Immunol., 2001, 108, 634-8; and Nilsson et al., Pediatr. AllergyImmunol., 2015, 26, 119-25). Other allergenic components, including alpha ( )- / beta ( )-,and gamma ( )-gliadins, as well as high molecular weight (HMW)-glutenin, and lowmolecular weight (LMW)-glutenin have also been identified as allergenic proteins for IgE- mediated wheat allergy (Srisuwatchari et al., Asian Pac. J. Allergy Immunol., 2022, 40, 263-8; and Rutrakool et al., Asian Pac. J. Allergy Immunol., 2023). Until recently, a novel tool called the bead-based epitope assay (BBEA), which employs machine learning techniques, has been developed to predict clinical reactivity, differentiate clinical phenotypes, and forecast treatment outcomes in patients with some food allergies. The BBEA has shown promising results in studies related to peanut (Suprun et al., Allergy, 2022, 77, 3061-9; Suarez-Farinas et al., J. Allergy Clin. Immunol., 2021, 148, 835- 42; Suprun et al., J. Allergy Clin. Immunol., 2020, 146, 1080-8; and Suárez-Fariñas et al., 27527-0242WO1; ISMMS Ref.231101 Allergy, 2021, 76, 3789-97), cow’s milk (Suárez-Fariñas et al., J. Allergy Clin. Immunol., 2019, 143, 1038-46; and Sackesen et al., Allergy, 2019, 74, 327-36), and egg allergies (Suprun et al., Allergy, 2020, 75, 2633-43; and Suprun et al., Int. Arch Allergy Immunol., 2022, 183, 249- 61). However, to date, this technique has not been applied to wheat allergies. Summary The present disclosure provides methods for diagnosing a wheat allergy, and / or severity of a wheat allergy, in a subject comprising: a) contacting one or more wheat peptides with serum or plasma obtained from the subject under conditions sufficient to permit binding of one or more allergy associated immunoglobulins (AAIs) in the serum or plasma to the one or more wheat peptides, wherein the one or more wheat peptides are coupled to a solid support, to form one or more AAI-peptide-solid support complexes; b) binding an AAI-specific labeling reagent to the AAI-peptide-solid support complex; and c) detecting binding of the AAI-specific labeling reagent to each AAI-peptide-solid support complex to identify one or more wheat peptides bound to the AAI in the serum or plasma of the subject; wherein recognition of at least one wheat peptide by an AAI in the serum or plasma of the subject indicates that the subject is allergic to wheat, and wherein the greater the number of wheat peptides recognized and / or the greater the level of wheat peptide binding the more severe the wheat allergy. The present disclosure also provides methods for detecting development of clinical tolerance to wheat in a subject that is allergic to wheat comprising: a) contacting one or more wheat peptides with serum or plasma obtained from the subject under conditions sufficient to permit binding of one or more allergy associated immunoglobulins (AAIs) in the serum or plasma to the one or more wheat peptides, wherein the one or more wheat peptides are coupled to a solid support, to form one or more AAI-peptide-solid support complexes; b) binding an AAI-specific labeling reagent to the AAI-peptide-solid support complex; c) detecting binding of the AAI-specific labeling reagent to each AAI-peptide-solid support complex to identify one or more wheat peptides bound to the AAI in the serum or plasma of the subject; and d) comparing the identified one or more wheat peptides bound 27527-0242WO1; ISMMS Ref.231101 to the AAI in the serum or plasma of the subject, or the concentration of the AAI in the serum or plasma of the subject, with a previously identified panel of one or more wheat peptides bound to the AAI in the serum or plasma of the subject, or a previous concentration of the AAI in the serum or plasma of the subject; wherein development of clinical tolerance to wheat is indicated when: i) the subsequent number of wheat peptides recognized by IgE AAI in the serum or plasma of the subject, and / or the subsequent concentration of AAI IgE in the serum or plasma of the subject, is less than the previously identified number of wheat peptides recognized by AAI IgE in the serum or plasma of the subject, and / or less than the previous concentration of AAI IgE in the serum or plasma of the subject; and / or ii) the subsequent number of wheat peptides recognized by IgG4 AAI in the serum or plasma of the subject, and / or the subsequent concentration of AAI IgG4 in the serum or plasma of the subject, is greater than the previously identified number of wheat peptides recognized by AAI IgG4 in the serum or plasma of the subject, and / or greater than the previous concentration of AAI IgG4 in the serum or plasma of the subject. The present disclosure also provides methods for detecting an increase in intensity of allergy or adverse event during treatment of allergy to wheat over time in a subject that is allergic to wheat comprising: a) contacting one or more wheat peptides with serum or plasma obtained from the subject under conditions sufficient to permit binding of one or more allergy associated immunoglobulins (AAIs) in the serum or plasma to the one or more wheat peptides, wherein the one or more wheat peptides are coupled to a solid support, to form one or more AAI-peptide-solid support complexes; b) binding an AAI-specific labeling reagent to the AAI-peptide-solid support complex; c) detecting binding of the AAI-specific labeling reagent to each AAI-peptide-solid support complex to identify one or more wheat peptides bound to the AAI in the serum or plasma of the subject; and d) comparing the identified one or more wheat peptides bound to the AAI in the serum or plasma of the subject, or the concentration of the AAI in the serum or plasma of the subject, with a previously identified panel of one or more wheat peptides bound to the AAI in the serum of the subject, or a previous concentration of the AAI in the serum or plasma of the subject; wherein an increased intensity of the allergic response to wheat is indicated when the subsequent number or pattern of reactivity of wheat peptides recognized by AAI in the 27527-0242WO1; ISMMS Ref.231101 serum or plasma of the subject, or the subsequent concentration of AAI in the serum or plasma of the subject, is greater than the previously identified number or pattern of reactivity of wheat peptides recognized by AAI in the serum or plasma of the subject, or greater than the previous concentration of AAI in the serum or plasma of the subject. The present disclosure also provides methods of sensitizing an infant to one or more wheat allergens to induce tolerance or non-allergy to wheat comprising administering one or more wheat peptides to the infant, wherein the one or more wheat peptides are derived from low molecular weight glutenin (lmw), alpha / beta gliadin (alb), gamma gliadin (gam), omega-5-gliadin (omg), and / or high molecular weight glutenin (hmw). The present disclosure also provides sets of allergenic epitope-containing wheat peptides comprising a plurality of wheat peptides comprising at least two peptides derived from low molecular weight glutenin (lmw), alpha / beta gliadin (alb), gamma gliadin (gam), omega-5-gliadin (omg), and / or high molecular weight glutenin (hmw). The present disclosure also provides kits comprising: a) one or more allergenic epitope-containing wheat peptides derived from low molecular weight glutenin (lmw), alpha / beta gliadin (alb), gamma gliadin (gam), omega-5-gliadin (omg), and / or high molecular weight glutenin (hmw), wherein each wheat peptide is coupled to a solid support; and b) an allergy associated immunoglobulin (AAI)-specific labeling reagent; packaged together and including instructions for use. Brief Description Of The Drawings The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee. The accompanying figures, which are incorporated in and constitute a part of this specification, illustrate several features of the present disclosure. Figure 1 shows diversity binding of es-IgE (Panel A), es-IgG4 (Panel B), and es-IgG1 (Panel C) of five wheat peptides compared between wheat-allergic or wheat-tolerant subjects and presented as box plot with median and 95% CI for each group. 27527-0242WO1; ISMMS Ref.231101 Figure 2 shows diversity binding of es-IgE (Panel A), es-IgG4 (Panel B), and es-IgG1 (Panel C) of five wheat peptides compared between each wheat allergy clinical phenotype or wheat-tolerant subjects. Figure 3 shows BORUTA derived average importance of each epitope and immunoglobulin, with the vertical line indicating mean importance for each Immunoglobulin (Panel A); distributions of Importance across Immunoglobulin indicates that es-IgE epitopes are significantly more important than IgG4 and IgG1 in predicting wheat allergy (Panel B); importance for es-IgE epitopes across 5 wheat proteins illustrating that gamma-gliadin and omega-5-gliagin have the higher predictive ability (ANOVA, p <0.0001) (Panel C); boxplot of the importance across simulation for each es-IgE epitope ranked by median importance (Panel D); and univariate logistic regression analysis of es-IgE epitopes, 10-fold cross-validation AUC results in the training dataset ranked by most predictive epitopes (Panel E). Figure 4 shows ROC curves comparing predictions based on sIgE Wheat to that of the top 4 BBEAR models in the training data; AUC for each model and the p-value comparing each BBEAR model against IgE Wheat (DeLong’s test) are presented and indicate superiority of BEAR (Panel A); similar to Panel A but comparing against SPT using a subset of 92 patients with available SPT (Panel B); comparing BBEAR Wheat and sIgE Allergy scores; the dark lines represent the allergy threshold for each model (sIgE dashed horizontal line, BBEAR solid vertical line) with points above deemed allergic and below not allergic for sIgE Allergy Scores; the top 2 models are presented illustrating high discrimination in the training set with 12 misclassifications between BBEAR model’s 1 and 2 each using a unique combination of gamma-gliadin and omega-5-gliagin proteins (Panel C). Figure 5 shows PCA plot of the SI / SAI and FARI cohort colored by the wheat-allergic and wheat-tolerant groups. Figure 6 shows average binding of es-IgE (Panel A), es-IgG4 (Panel B), and es-IgG1 (Panel C) of five wheat peptides compared between wheat-allergic or wheat-tolerant subjects and presented as box plot with median and 95% CI for each group. Figure 7 shows average binding of es-IgE (Panel A), es-IgG4 (Panel B), and es-IgG1 (Panel C) of five wheat peptides compared between each wheat allergy clinical phenotype 27527-0242WO1; ISMMS Ref.231101 (anaphylaxis, isolated cutaneous symptoms, or wheat dependent exercise-induced anaphylaxis) or wheat-tolerant subjects and presented as box plot with median and 95% CI for each group. Figure 8 shows BORUTA derived decisions for each protein stratified by immunoglobulin; specifically, IgE and IgG4 both contained epitopes which were deemed important for predicting wheat allergy status. Figure 9 shows distributions of importance for each immunoglobulin stratified by protein. Immunoglobulin IgE was found to have significantly higher average importance for alpha / beta-gliadin, gamma-gliadin, and omega-5-gliadin proteins. Figure 10 shows AUCs of top 10 models for IgE comparing average IgE and plate- adjusted average IgE across 10-fold cross-validation, training, and testing datasets; plate adjustment was not found to improve model performance but was somewhat comparable to average IgE which had consistently higher AUC values across datasets. Figure 11 shows distribution of 10-fold cross-validation AUCs for model combinations illustrating the utility of progressively adding additional important epitopes to models with up to 4 unique epitopes; there were significant differences in the average AUC’s up until quadrivariate models indicating diminishing returns on adding a fifth epitope. Description Of Embodiments The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. This present disclosure represents the first use of BBEA to determine sequential epitope-specific IgE (es-IgE), IgG4 (es-IgG4), and IgG1 (es-IgG1) antibodies in wheat-allergic and wheat-sensitive but tolerant children, and distinguishing the clinical manifestations of their wheat allergy. Before describing several exemplary embodiments, it is to be understood that the embodiments are not limited to the details of construction or process steps set forth in the following description. The embodiments described herein are capable of modifications and of being practiced or being carried out in various ways. 27527-0242WO1; ISMMS Ref.231101 Reference throughout the present disclosure to “some embodiments,” or derivations thereof, means that a particular feature, structure, material, or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, the appearances of the phrases such as “in some embodiments,” in various places throughout the present disclosure is not necessarily referring to the same embodiment, but can generally be attributed to any other embodiment. Furthermore, the particular features, structures, materials, or characteristics may be combined in any suitable manner in one or more embodiments. As used herein, the terms “allergy associated immunoglobulin” and “AAI” refer to immunoglobulins in sera that mediate hypersensitivity to wheat allergens. These include one or more of IgE, IgA, IgM, and IgG (including IgG4). As used herein, the terms “reactive”, “reactivity”, “recognize” and the like refer to the ability of an allergy associated immunoglobulin to bind to an allergenic epitope containing peptide. The level of reactivity indicates the concentration of AAI in the serum or plasma, with high reactivity associated with higher AAI concentrations and lower reactivity associated with lower AAI concentrations. The relative AAI concentration (i.e., the relative serum or plasma reactivity) is determined by the amount of signal detected in the assay. The level of reactivity of AAI to allergenic epitope containing peptides also indicates the intensity of the allergic response (i.e., higher reactivity is associated with a more intense allergic reaction). As used herein, the term “clinical tolerance” refers to immunological tolerance to a wheat allergen that is developed by an allergic subject as a result of exposure to the allergen (i.e., tolerance developed as a result of immunotherapy). As used herein, the term “natural tolerance” refers to immunological tolerance to a wheat allergen that is developed by an allergic subject as a biochemical process over time, either as a result of natural exposure to the allergen during a lifetime or in the absence of exposure. A) Peptides 27527-0242WO1; ISMMS Ref.231101 The present disclosure provides sets of allergenic epitope-containing wheat peptides comprising a plurality of wheat peptides comprising at least two peptides derived from low molecular weight glutenin (lmw), alpha / beta gliadin (alb), gamma gliadin (gam), omega-5-gliadin (omg), and / or high molecular weight glutenin (hmw). In some embodiments, each wheat peptide comprises from about from about 6 amino acids to about 30 amino acids, from about 7 amino acids to about 20 amino acids, from about 10 amino acids to about 18 amino acids, or from about 12 amino acids to about 16 amino acids. In some embodiments, each wheat peptide comprises 15 amino acids. In some embodiments, the plurality of wheat peptides comprises at least 2 wheat peptides, at least 3 wheat peptides, at least 5 wheat peptides, at least 10 wheat peptides, at least 15 wheat peptides, at least 20 wheat peptides, or at least 25 wheat peptides. In some embodiments, the plurality of wheat peptides comprises from about 2 to about 25 wheat peptides, from about 2 to about 20 wheat peptides, from about 2 to about 15 wheat peptides, or from about 2 to about 10 wheat peptides. In some embodiments, the plurality of wheat peptides comprises from about 2 to about 25 wheat peptides, from about 3 to about 20 wheat peptides, from about 5 to about 15 wheat peptides, from about 8 to about 15 wheat peptides, from about 10 to about 15 wheat peptides, from about 12 to about 15 wheat peptides, from about 10 to about 14 wheat peptides, or from about 12 to about 14 wheat peptides. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides derived from lmw comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, and SEQ ID NO: 13. In some embodiments, the wheat peptide derived from lmw comprises an amino acid sequence SEQ ID NO: 8. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides derived from alb comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, 27527-0242WO1; ISMMS Ref.231101 SEQ ID NO: 24, SEQ ID NO: 25, and SEQ ID NO: 26. In some embodiments, the one or more wheat peptides derived from alb comprise an amino acid sequence SEQ ID NO: 17 or SEQ ID NO: 20. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides derived from gam comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, and SEQ ID NO: 45. In some embodiments, the one or more wheat peptides derived from gam comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 27, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 40, SEQ ID NO: 43, and SEQ ID NO: 44. In some embodiments, the one or more wheat peptides derived from gam comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 43, and SEQ ID NO: 44. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides derived from omg comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, and SEQ ID NO: 63. In some embodiments, the one or more wheat peptides derived from omg comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 59, and SEQ ID NO: 62. In some embodiments, the one or more wheat peptides derived from omg comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, and SEQ ID NO: 57. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides derived from hmw comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 27527-0242WO1; ISMMS Ref.231101 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, and SEQ ID NO: 79. In some embodiments, the wheat peptide derived from hmw comprises an amino acid sequence SEQ ID NO: 74. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 27, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 40, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 62, and SEQ ID NO: 74. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, and SEQ ID NO: 74. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides derived from gamma gliadin and / or omega-5-gliadin. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, and SEQ ID NO: 57. It is to be understood that although the allergenic epitope-containing peptides disclosed herein are described as specific embodiments having specific amino acid sequences, one skilled in the art will recognize that each such peptide may be shifted in either the N-terminal or C-terminal direction of the protein from which it is derived to obtain a related peptide sequence that still contains the relevant epitope but in which the relevant epitope is flanked by different amino acids than specified. Accordingly, in all embodiments, the allergenic epitope containing peptides can have amino acid sequences that overlap with the disclosed peptide sequences by 2, 4, 6, or 8 or more contiguous amino acids. 27527-0242WO1; ISMMS Ref.231101 It will also be recognized that analysis of all seventy-nine of the peptides represented by SEQ ID NOs: 1-79 is not always necessary to obtain useful results in the methods described herein. It is possible to employ a sufficient number of peptides selected from among the peptides represented by SEQ ID NOs: 1-79 (as described herein) to provide a statistically reliable result. For example, if the wheat allergy status of a subject is not known, it is generally desirable to analyze a greater number of allergenic epitope-containing peptides selected from among the peptides represented by SEQ ID NOs: 1-79 (or among the peptides represented by SEQ ID NO: 8, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 27, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 40, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 62, and SEQ ID NO: 74, or among the peptides represented by SEQ ID NO: 8, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, and SEQ ID NO: 74, or among the peptides represented by SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, and SEQ ID NO: 57) to ensure that mild to moderate wheat allergy, that may involve reactivity with only a few of the peptides represented by SEQ ID NOs: 1-79, is detectable. Conversely, if a subject is known to have high-intensity wheat allergy, fewer allergenic epitope-containing peptides selected from among the peptides represented by SEQ ID NOs: 1-79 may be sufficient to detect changes in allergy intensity or development of clinical tolerance, because a larger number of the peptides represented by SEQ ID NOs: 1-79 will be initially reactive. However, because changes in allergy intensity and development of clinical tolerance are evidenced by changes in the number of peptides reactive with sera as well as changes in concentration of serum IgE reactive with a particular peptide, it is particularly desirable to include in the assays a large enough set of peptides selected from among the peptides represented by SEQ ID NOs: 1-79 (or among the peptides represented by SEQ ID NO: 8, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 27, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 40, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 62, 27527-0242WO1; ISMMS Ref.231101 and SEQ ID NO: 74, or among the peptides represented by SEQ ID NO: 8, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, and SEQ ID NO: 74, or among the peptides represented by SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, and SEQ ID NO: 57) to ensure that changes with respect to a peptide that is diagnostic for a particular subject are not missed. Accordingly, the plurality of allergenic epitope-containing peptides selected from among peptides represented by SEQ ID NOs: 1-79 for use in any of the methods described herein may represent all 79 peptides of SEQ ID NOs: 1-79, a subset of 2-25 wheat peptides, 3-20 wheat peptides, 5-15 wheat peptides, 8-15 wheat peptides, 10-15 wheat peptides, 12-15 wheat peptides, 10-14 wheat peptides, or 12-14 wheat peptides B) Methods of diagnosing wheat allergy The present disclosure also provides methods for diagnosing a wheat allergy, and / or severity of a wheat allergy, in a subject comprising: a) contacting one or more wheat peptides with serum or plasma obtained from the subject under conditions sufficient to permit binding of one or more allergy associated immunoglobulins (AAIs) in the serum or plasma to the one or more wheat peptides, wherein the one or more wheat peptides are coupled to a solid support, to form one or more AAI-peptide-solid support complexes; b) binding an AAI-specific labeling reagent to the AAI-peptide-solid support complex; and c) detecting binding of the AAI-specific labeling reagent to each AAI-peptide-solid support complex to identify one or more wheat peptides bound to the AAI in the serum or plasma of the subject; wherein recognition of at least one wheat peptide by an AAI in the serum or plasma of the subject indicates that the subject is allergic to wheat, and wherein the greater the number of wheat peptides recognized and / or the greater the level of wheat peptide binding the more severe the wheat allergy. In some embodiments, each wheat peptide comprises from about from about 6 amino acids to about 30 amino acids, from about 7 amino acids to about 20 amino acids, 27527-0242WO1; ISMMS Ref.231101 from about 10 amino acids to about 18 amino acids, or from about 12 amino acids to about 16 amino acids. In some embodiments, each wheat peptide comprises 15 amino acids. In some embodiments, the plurality of wheat peptides comprises at least 2 wheat peptides, at least 3 wheat peptides, at least 5 wheat peptides, at least 10 wheat peptides, at least 15 wheat peptides, at least 20 wheat peptides, or at least 25 wheat peptides. In some embodiments, the plurality of wheat peptides comprises from about 2 to about 25 wheat peptides, from about 2 to about 20 wheat peptides, from about 2 to about 15 wheat peptides, or from about 2 to about 10 wheat peptides. In some embodiments, the plurality of wheat peptides comprises from about 2 to about 25 wheat peptides, from about 3 to about 20 wheat peptides, from about 5 to about 15 wheat peptides, from about 8 to about 15 wheat peptides, from about 10 to about 15 wheat peptides, from about 12 to about 15 wheat peptides, from about 10 to about 14 wheat peptides, or from about 12 to about 14 wheat peptides. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides derived from lmw comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, and SEQ ID NO: 13. In some embodiments, the wheat peptide derived from lmw comprises an amino acid sequence SEQ ID NO: 8. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides derived from alb comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, and SEQ ID NO: 26. In some embodiments, the one or more wheat peptides derived from alb comprise an amino acid sequence SEQ ID NO: 17 or SEQ ID NO: 20. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides derived from gam comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, 27527-0242WO1; ISMMS Ref.231101 SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, and SEQ ID NO: 45. In some embodiments, the one or more wheat peptides derived from gam comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 27, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 40, SEQ ID NO: 43, and SEQ ID NO: 44. In some embodiments, the one or more wheat peptides derived from gam comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 43, and SEQ ID NO: 44. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides derived from omg comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, and SEQ ID NO: 63. In some embodiments, the one or more wheat peptides derived from omg comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 59, and SEQ ID NO: 62. In some embodiments, the one or more wheat peptides derived from omg comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, and SEQ ID NO: 57. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides derived from hmw comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, and SEQ ID NO: 79. In some embodiments, the wheat peptide derived from hmw comprises an amino acid sequence SEQ ID NO: 74. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 27, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 40, SEQ ID NO: 43, 27527-0242WO1; ISMMS Ref.231101 SEQ ID NO: 44, SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 62, and SEQ ID NO: 74. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, and SEQ ID NO: 74. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides derived from gamma gliadin and / or omega-5-gliadin. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, and SEQ ID NO: 57. In some embodiments, each of the wheat peptides comprises a linker for coupling to the solid support. In some embodiments, the linker is -PEG12-biotin. In some embodiments, the linker can comprise 3, 6, 9, or 12 carbons. In some embodiments, the biotin can be replaced with click chemistry linkers (e.g., azide-DBCO, amine-NHS ester, thiol- malamide, hydrazone, etc.). In some embodiments, the solid support is a microsphere bead, glass array, silicone array, membrane, or microtiter plate. In some embodiments, each of the solid supports, such as a bead, microtiter plate well, or discrete location on the chromatographic material, is occupied by a single peptide. The solid supports are then contacted with serum or plasma obtained from the subject under conditions appropriate for specific binding of anti-peptide AAI in the serum or plasma (if present) to the peptide on each solid support or discrete location on a solid support to form a peptide-AAI complex on the solid support. Any peptide-AAI complex formed on a solid support is then detected by contacting the complex on each solid support or discrete location on the solid support with a labeling reagent that specifically binds to the complex, typically by binding to the immobilized serum or plasma AAI antibody. A single labeling reagent will generally be used for universal detection of all complexes. The specific peptide-AAI complex may then be identified by its position on the 27527-0242WO1; ISMMS Ref.231101 microtiter plate or chromatographic support. When the solid support to which each peptide is conjugated has different spectral properties, the specific peptide-AAI complex may also be identified by analysis of the spectral properties of the solid support associated with the peptide-AAI complex, once the presence of a complex is identified via a detectable signal from the labeling reagent bound to the complex. As an example, the presence or absence of a peptide-AAI complex in each well of a microtiter plate can be determined by binding to the complex an anti-human AAI antibody that is conjugated to a reporter moiety, such as a fluorescent dye, a chromogenic dye, an enzyme label or a radioactive label. Alternatively, the anti-human AAI antibody may be conjugated to a reporter moiety that is not directly detectable, so specific binding of a second, directly detectable reporter moiety to the labeling reagent is necessary for analysis of binding. In some embodiments, the AAI is IgG, IgM, IgA, and / or IgE. In some embodiments, the AAI is IgG or IgE. In some embodiments, the AAI is IgE. In some embodiments, the AAI is IgG. In some embodiments, the IgG is IgG4. In some embodiments, the AAI-specific labeling reagent is a detectably labeled anti-human IgG4 antibody, detectably labeled anti-human IgM antibody, detectably labeled anti-human IgA antibody, and / or a detectably labeled anti-human IgE antibody. In some embodiments, the AAI-specific labeling reagent is a detectably labeled anti-human IgG antibody and / or a detectably labeled anti-human IgE antibody. In some embodiments, the detectable label is chosen from phycoerythrin, a fluorescent dye, horse radish peroxidase (HRP), and alkaline phosphatase. In some embodiments, the labeling reagent may be conjugated to a first reporter moiety that is directly detectable, such as a fluorescent dye, radiolabel, or colored dye. In some embodiments, a phycoerythrin (PE) molecule can be directly coupled to an anti-allergy associated immunoglobulin and used for detection. Alternately, the first reporter moiety may be a reporter moiety that is indirectly detectable (e.g., an enzyme label of chromogenic dye) and a specific binding partner for the first reporter moiety can be conjugated to a directly detectable label (the second reporter moiety). For example, a biotin-conjugated anti-AAI antibody can be used in combination with a streptavidin-conjugated fluorescent dye for detection of the biotin-conjugated anti- 27527-0242WO1; ISMMS Ref.231101 AAI. In some embodiments, the detectable label can be observed via silver staining, quantum dots, or refraction methodologies. In some embodiments, the detection of the binding of the AAI-specific labeling reagent to each AAI-peptide-solid support complex is carried out by a multiplex peptide- bead assay for flow cytometric analysis or a lateral flow assay. Any of the foregoing embodiments may be in the form of a microarray immunoassay, wherein each of the plurality of allergenic epitope-containing peptides is bound to a separate well of a microtiter plate and reacted with serum to bind AAI. Bound AAI is detected by binding of an AAI- specific labeling reagent, for example an anti-AAI antibody conjugated to a reporter moiety, such as a fluorescent label. Fluorescence of the bound labeling reagent indicates the presence in the serum or plasma of an antibody to the allergenic epitope contained in the peptide bound to the well. The plurality of allergenic epitope-containing peptides may also be used in a lateral flow immunoassay format, wherein each peptide is immobilized in a discrete area on a porous or chromatographic support, and the serum or plasma is wicked through the support to contact the peptides for binding of AAI to the peptides. In this assay, the AAI-specific labeling reagent may comprise a chromophore or dye conjugated to anti- AAI antibody. The labeling reagent is also wicked through the support to contact the peptide-AAI complexes for binding of the labeling reagent to the complex, which indicates the presence or absence in the serum or plasma of an antibody to the allergenic epitope contained in the peptide immobilized at each discrete location of the support. Any of the foregoing embodiments may also be in the form of a flow cytometry assay in which each allergenic epitope-containing peptide is conjugated to a separately identifiable solid support suitable for analysis by flow cytometry, such as a bead. Typically, the peptide is conjugated to the solid support by binding to a peptide-specific capture antibody on the solid support or by chemical linkage to the solid support. In some embodiments, the bead with the conjugated allergenic epitope-containing peptide is contacted with the serum or plasma of a subject to bind any peptide-specific AAI that is bound to the bead via the peptide, thus forming a peptide-AAI complex on the bead. An AAI-specific labeling reagent comprising, for example, a fluorescent reporter moiety is then bound to the peptide-AAI complexes and the beads are analyzed quantitatively or 27527-0242WO1; ISMMS Ref.231101 qualitatively by flow cytometry. This detects fluorescence from the bound labeling reagent associated with each bead to which an allergenic epitope-containing peptide is conjugated, thereby identifying the peptide and the presence in the serum of AAI that is reactive to it. Presence of AAI reactive to at least one of a plurality of allergenic epitope-containing peptides indicates that the subject is allergic to wheat, and changes over time in the number of reactive peptides, or changes over time in the concentration of AAI reactive to one or more peptides, indicates an increase in intensity of the allergy, a decrease in the intensity of the allergy, or development of clinical tolerance over that time period. In some embodiments, the flow cytometry assay may be a multiplex assay, such as the LUMINEX xMAP technology, which uses a microsphere array platform for quantitation and detection of peptides and proteins. Each of the plurality of allergenic epitope- containing peptides is bound to a set of beads with different spectral properties which can be used to identify the associated allergenic epitope-containing peptide by flow cytometry. The sets of beads are then contacted with serum or plasma of a subject to bind peptide- recognizing AAI to each bead to form a peptide-AAI complex on the bead, and an AAI- specific labeling reagent comprising, for example, a fluorescent reporter moiety bound to the AAI of the complex. The beads are analyzed by monitoring the spectral properties of each bead and the amount of associated fluorescence from the bound labeling reagent. This process allows identification of the peptide on the bead, and the presence or absence of serum or plasma AAI that is reactive to it. Results of the assay are interpreted as discussed herein. A particularly useful quantitative assay for use in any of the methods described herein is a multiplex peptide-bead assay for flow cytometric analysis, such as the LUMINEX exMAP multiplex bead assay, which is a high-throughput alternative to the ELISA. In this assay, polystyrene beads (microspheres) dyed with distinct proportions of red and near- infrared fluorophores are used as the solid support. The peptides may be chemically linked to the beads or bound thereto through peptide-specific capture antibodies coated on the beads. The proportions of the fluorophores define a “spectral address” for each bead population that can be identified by a flow cytometer using digital signal processing. Detection of a third fluorescence color is used for measurement of the fluorescence 27527-0242WO1; ISMMS Ref.231101 intensity of the reporter moiety of the labeling reagent bound to the bead. Multiple analytes can be detected simultaneously by binding each peptide to a bead having a specific “spectral address.” Contacting the beads with serum or plasma containing AAI that are specific for the peptide bound to it is followed by addition of anti-human AAI antibodies conjugated to a reporter moiety. In some embodiments, the reporter moiety of the anti- human AAI is biotin and binding to phycoerythyrin (PE)-conjugated streptavidin provides the fluorescent signal for detection. Following binding of the labeling reagent, the beads are analyzed on a dual-laser flow-based detection instrument, such as the LUMINEX 200 or Bio- Rad BIO-PLEX analyzer. One laser classifies the bead and identifies the peptide bound to it. The second laser determines the magnitude of the reporter-derived signal, which is in direct proportion to the amount of bound serum or plasma AAI. An alternative assay format is a lateral flow or immunochromatographic assay. In such an assay, the selected allergenic epitope containing peptide(s) are immobilized on the porous support and serum or plasma containing the AAI is wicked into contact with the peptide(s) to form immunocomplexes. Further migration of the immunocomplex through the porous support brings it into contact with a specific capture reagent for detection of the immunocomplex using appropriate detection reagents. In some embodiments, following exposure to wheat allergens, when at least one peptide is moderately or highly reactive with serum or plasma AAI (S / N > 2) and reactivity of one or more of the reactive peptides does not decrease at least 2-fold within about six months, the subject is diagnosed as having wheat allergy. In some embodiments, the methods for diagnosis of wheat allergy are qualitative methods (i.e., based only on presence or absence of AAI reactive to each selected peptide). The presence of AAI moderately or highly reactive with any selected peptide can be considered to indicate some degree of wheat allergy, provided that the reactivity does not substantially diminish within a short period of time such as about six months. The methods may also be semi-quantitative (i.e., the greater the number of peptides reactive with the serum or plasma of the subject, the relatively more intense the allergy and, conversely, the fewer the number of reactive peptides, the relatively less intense the allergy). Serum orplasma reactivity with 2-5 of the peptides may indicate mild to moderate wheat allergy with 27527-0242WO1; ISMMS Ref.231101 reactivity within the lower end of this range generally characterized as mild wheat allergy. Serum reactivity with 5-30, 5-25, 8-25, or 12-15 or more of the peptides may indicate moderate to severe wheat allergy, with reactivity within the lower end of this range generally characterized as moderate wheat allergy. In some embodiments, wheat allergy can be diagnosed if the subject has antibodies to at least two, or more, of the peptides described herein. In some embodiments, for analyzing binding to individual wheat peptides, recognition of the peptide by an AAI in the serum or plasma is significant if the value of binding is 0.1, 0.2, or 0.3. In some embodiments, for analyzing binding to individual wheat peptides, recognition of the peptide by an AAI in the serum or plasma is significant if the value of binding is 2 standard deviations over background (i.e., from a non-allergic background). In some embodiments, for analyzing binding to individual wheat peptides, recognition of the peptide by an AAI in the serum or plasma is determined by mean fluorescence intensity (MFI). In some embodiments, the methods for diagnosis of wheat allergy are quantitative methods (based on quantitation of the level of AAI reactivity to each selected peptide). In some embodiments, the level of reactivity correlates with the amount of labeling reagent bound to the peptide-AAI complex, with higher levels of signal from the reporter moiety indicating a higher concentration of a particular peptide-specific AAI in the serum or plasma. To obtain the amount or concentration of reporter moiety bound to a particular peptide-AAI complex, the quantity of fluorescence from a fluorescent dye, intensity of color from a colored or chromogenic dye or from an enzyme label, or quantity of radioactivity from a radioactive label is positively correlated with the amount of bound AAI in the complex and therefore its concentration. Methods for measuring these parameters are known in the art. The relative quantities of AAI reactive with any of the peptides can be considered to indicate the degree or intensity of wheat allergy. That is, the higher the level of reactivity of the plurality of selected peptides, or of one or more peptides within the selected peptides, the more intense the allergy. Conversely, the lower the level of reactivity of the plurality of selected peptides, or of one or more peptides within the selected peptides, the less intense the allergy. 27527-0242WO1; ISMMS Ref.231101 The serum or plasma of individuals with mild allergy are reactive with fewer peptides than the serum or plasma of individuals with more intense allergy. The present disclosure, therefore, not only provides methods for diagnosing wheat allergy, it provides methods for determining the intensity of the allergy and methods for determining changes in the intensity of the allergy over time, including detection of development of clinical tolerance to wheat. In some embodiments, the number of allergenic epitope-containing peptides that are reactive with the serum or plasma of an allergic subject has a positive correlation with the intensity of the allergic response, i.e., reactivity with fewer peptides indicates a milder allergic response to wheat and reactivity with more peptides indicates the subject is more highly allergic to wheat. In some embodiments, the intensity of binding of serum IgE to the peptides (e.g., a measure of IgE concentration in the serum or plasma) correlates with the intensity of the allergic response (i.e., weaker reactivity with all peptides, or with a subset of all the peptides, indicates a more moderate allergic response compared to stronger reactivity with all peptides or with the subset of peptides). Previously known assays for wheat allergy based on analysis of peptide epitopes in wheat proteins are competitive immunoassays which rely on analysis of the relative affinity of binding of IgE and IgG4 to the epitope. The affinity of antibody binding is believed to be related to whether or not the subject will develop clinical tolerance to wheat. In contrast, in some embodiments, the methods described herein are partly based on an analysis of the presence or absence of AAI binding to each individual peptide in a set of wheat protein epitopes that correlates with a diagnosis of wheat allergy, with the intensity of the allergic response, and with the potential of a patient to either develop tolerance or experience an increased allergic response based on the number of epitopes (i.e., peptides) bound by IgE in the serum or plasma of the subject. In some embodiments, the methods described herein are partly based on analysis of the concentration of AAIs in the serum or plasma that are reactive with each of the allergenic epitope-containing peptides, which also correlates with the intensity of the allergic response. As used herein, reference to “non-reactive” or “negative” reactivity with an allergenic epitope-containing peptide means a signal-to-noise ratio (S / N) in the assay that is 27527-0242WO1; ISMMS Ref.231101 less than about 2. A typical background signal (N) is that generated by a pool of serum or plasma from non-allergenic individuals. Alternately, negative peptides can be used as the basis for establishing the background signal. As used herein, reference to “weak” or “moderate” reactivity with an allergenic epitope-containing peptide means a S / N of about 2-10, although this value may vary depending on the peptide and the allergy. As used herein, reference to “high” or “strong” reactivity with an allergenic epitope-containing peptide means a S / N of greater than about 10. Peptides useful in methods for diagnosis of wheat allergy or tolerance thereto, and for detecting increases and decreases in the intensity of the allergy may also include peptides containing non-reactive epitopes of wheat proteins. These peptides are useful as negative controls. In some embodiments, the analysis of binding of the labeling reagent to each peptide-AAI complex may include analysis of the extent of binding, which indicates a concentration of each peptide-specific AAI in the serum or plasma. A low to moderate serum or plasma reactivity with all the peptides, or with a subset thereof, indicates a lower concentration of peptide-specific AAI in the serum and mild to moderate wheat allergy, whereas high serum or plasma reactivity with all of the peptides, or a subset thereof, indicates a higher concentration of peptide-specific AAI in the serum and more severe wheat allergy. The analysis of binding for diagnosis of wheat allergy may employ either the number of peptides reactive with serum or plasma, the extent of binding of serum or plasma AAI to the peptides, or both. C) Methods of detecting development of clinical tolerance The present disclosure also provides methods for detecting development of clinical tolerance to wheat in a subject that is allergic to wheat comprising: a) contacting one or more wheat peptides with serum or plasma obtained from the subject under conditions sufficient to permit binding of one or more allergy associated immunoglobulins (AAIs) in the serum or plasma to the one or more wheat peptides, wherein the one or more wheat peptides are coupled to a solid support, to form one or more AAI-peptide-solid support complexes; b) binding an AAI-specific labeling reagent to the AAI-peptide-solid support 27527-0242WO1; ISMMS Ref.231101 complex; c) detecting binding of the AAI-specific labeling reagent to each AAI-peptide-solid support complex to identify one or more wheat peptides bound to the AAI in the serum or plasma of the subject; and d) comparing the identified one or more wheat peptides bound to the AAI in the serum or plasma of the subject, or the concentration of the AAI in the serum or plasma of the subject, with a previously identified panel of one or more wheat peptides bound to the AAI in the serum or plasma of the subject, or a previous concentration of the AAI in the serum or plasma of the subject; wherein development of clinical tolerance to wheat is indicated when: i) the subsequent number of wheat peptides recognized by IgE AAI in the serum or plasma of the subject, and / or the subsequent concentration of AAI IgE in the serum or plasma of the subject, is less than the previously identified number of wheat peptides recognized by AAI IgE in the serum or plasma of the subject, and / or less than the previous concentration of AAI IgE in the serum or plasma of the subject; and / or ii) the subsequent number of wheat peptides recognized by IgG4 AAI in the serum or plasma of the subject, and / or the subsequent concentration of AAI IgG4 in the serum or plasma of the subject, is greater than the previously identified number of wheat peptides recognized by AAI IgG4 in the serum or plasma of the subject, and / or greater than the previous concentration of AAI IgG4 in the serum or plasma of the subject. In some embodiments, the age of a subject undergoing panel identification (e.g., initial, any subsequent, and / or final) can be from about 2 years old to about 50 years old. In some embodiments, each wheat peptide comprises from about from about 6 amino acids to about 30 amino acids, from about 7 amino acids to about 20 amino acids, from about 10 amino acids to about 18 amino acids, or from about 12 amino acids to about 16 amino acids. In some embodiments, each wheat peptide comprises 15 amino acids. In some embodiments, the plurality of wheat peptides comprises at least 2 wheat peptides, at least 3 wheat peptides, at least 5 wheat peptides, at least 10 wheat peptides, at least 15 wheat peptides, at least 20 wheat peptides, or at least 25 wheat peptides. In some embodiments, the plurality of wheat peptides comprises from about 2 to about 25 wheat peptides, from about 2 to about 20 wheat peptides, from about 2 to about 15 wheat peptides, or from about 2 to about 10 wheat peptides. In some embodiments, the plurality of wheat peptides comprises from about 2 to about 25 wheat peptides, from about 3 to 27527-0242WO1; ISMMS Ref.231101 about 20 wheat peptides, from about 5 to about 15 wheat peptides, from about 8 to about 15 wheat peptides, from about 10 to about 15 wheat peptides, from about 12 to about 15 wheat peptides, from about 10 to about 14 wheat peptides, or from about 12 to about 14 wheat peptides. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides derived from lmw comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, and SEQ ID NO: 13. In some embodiments, the wheat peptide derived from lmw comprises an amino acid sequence SEQ ID NO: 8. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides derived from alb comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, and SEQ ID NO: 26. In some embodiments, the one or more wheat peptides derived from alb comprise an amino acid sequence SEQ ID NO: 17 or SEQ ID NO: 20. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides derived from gam comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, and SEQ ID NO: 45. In some embodiments, the one or more wheat peptides derived from gam comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 27, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 40, SEQ ID NO: 43, and SEQ ID NO: 44. In some embodiments, the one or more wheat peptides derived from gam comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 43, and SEQ ID NO: 44. 27527-0242WO1; ISMMS Ref.231101 In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides derived from omg comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, and SEQ ID NO: 63. In some embodiments, the one or more wheat peptides derived from omg comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 59, and SEQ ID NO: 62. In some embodiments, the one or more wheat peptides derived from omg comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, and SEQ ID NO: 57. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides derived from hmw comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, and SEQ ID NO: 79. In some embodiments, the wheat peptide derived from hmw comprises an amino acid sequence SEQ ID NO: 74. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 27, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 40, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 62, and SEQ ID NO: 74. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, and SEQ ID NO: 74. 27527-0242WO1; ISMMS Ref.231101 In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides derived from gamma gliadin and / or omega-5-gliadin. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, and SEQ ID NO: 57. In some embodiments, each of the wheat peptides comprises a linker for coupling to the solid support, as described herein. In some embodiments, the linker is any of the linkers described herein. In some embodiments, the linker is -PEG12-biotin. In some embodiments, the solid support is a microsphere bead, glass array, silicone array, membrane, or microtiter plate, as described herein. In some embodiments, the AAI is any of the antibodies described herein. In some embodiments, the AAI-specific labeling reagent is any of the detectably labeled antibodies described herein. In some embodiments, the detectable label is any of the detectable labels described herein. In some embodiments, the detection of the binding of the AAI-specific labeling reagent to each AAI-peptide-solid support complex is carried out by a multiplex peptide- bead assay for flow cytometric analysis or a lateral flow assay as described herein. D) Methods of detecting increase in intensity of allergy The present disclosure also provides methods for detecting an increase in intensity of allergy or adverse event during treatment of allergy to wheat over time in a subject that is allergic to wheat comprising: a) contacting one or more wheat peptides with serum or plasma obtained from the subject under conditions sufficient to permit binding of one or more allergy associated immunoglobulins (AAIs) in the serum or plasma to the one or more wheat peptides, wherein the one or more wheat peptides are coupled to a solid support, to form one or more AAI-peptide-solid support complexes; b) binding an AAI-specific labeling reagent to the AAI-peptide-solid support complex; c) detecting binding of the AAI-specific labeling reagent to each AAI-peptide-solid support complex to identify one or more wheat 27527-0242WO1; ISMMS Ref.231101 peptides bound to the AAI in the serum or plasma of the subject; and d) comparing the identified one or more wheat peptides bound to the AAI in the serum or plasma of the subject, or the concentration of the AAI in the serum or plasma of the subject, with a previously identified panel of one or more wheat peptides bound to the AAI in the serum of the subject, or a previous concentration of the AAI in the serum or plasma of the subject; wherein an increased intensity of the allergic response to wheat is indicated when the subsequent number or pattern of reactivity of wheat peptides recognized by AAI in the serum or plasma of the subject, or the subsequent concentration of AAI in the serum or plasma of the subject, is greater than the previously identified number or pattern of reactivity of wheat peptides recognized by AAI in the serum or plasma of the subject, or greater than the previous concentration of AAI in the serum or plasma of the subject. In some embodiments, the subject may undergo a drift in the identity of allergic wheat peptides from one wheat peptide or one subset of wheat peptides to a different wheat peptide or subset of wheat peptides (a drift to a “hot spot” – see specific subsets of wheat epitopes described herein), which may indicate an increase in the intensity of the wheat allergy or the presence of an adverse event during therapy. In some embodiments, each wheat peptide comprises from about from about 6 amino acids to about 30 amino acids, from about 7 amino acids to about 20 amino acids, from about 10 amino acids to about 18 amino acids, or from about 12 amino acids to about 16 amino acids. In some embodiments, each wheat peptide comprises 15 amino acids. In some embodiments, the plurality of wheat peptides comprises at least 2 wheat peptides, at least 3 wheat peptides, at least 5 wheat peptides, at least 10 wheat peptides, at least 15 wheat peptides, at least 20 wheat peptides, or at least 25 wheat peptides. In some embodiments, the plurality of wheat peptides comprises from about 2 to about 25 wheat peptides, from about 2 to about 20 wheat peptides, from about 2 to about 15 wheat peptides, or from about 2 to about 10 wheat peptides. In some embodiments, the plurality of wheat peptides comprises from about 2 to about 25 wheat peptides, from about 3 to about 20 wheat peptides, from about 5 to about 15 wheat peptides, from about 8 to about 15 wheat peptides, from about 10 to about 15 wheat peptides, from about 12 to about 15 27527-0242WO1; ISMMS Ref.231101 wheat peptides, from about 10 to about 14 wheat peptides, or from about 12 to about 14 wheat peptides. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides derived from lmw comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, and SEQ ID NO: 13. In some embodiments, the wheat peptide derived from lmw comprises an amino acid sequence SEQ ID NO: 8. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides derived from alb comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, and SEQ ID NO: 26. In some embodiments, the one or more wheat peptides derived from alb comprise an amino acid sequence SEQ ID NO: 17 or SEQ ID NO: 20. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides derived from gam comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, and SEQ ID NO: 45. In some embodiments, the one or more wheat peptides derived from gam comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 27, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 40, SEQ ID NO: 43, and SEQ ID NO: 44. In some embodiments, the one or more wheat peptides derived from gam comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 43, and SEQ ID NO: 44. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides derived from omg comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 27527-0242WO1; ISMMS Ref.231101 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, and SEQ ID NO: 63. In some embodiments, the one or more wheat peptides derived from omg comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 59, and SEQ ID NO: 62. In some embodiments, the one or more wheat peptides derived from omg comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, and SEQ ID NO: 57. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides derived from hmw comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, and SEQ ID NO: 79. In some embodiments, the wheat peptide derived from hmw comprises an amino acid sequence SEQ ID NO: 74. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 27, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 40, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 62, and SEQ ID NO: 74. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, and SEQ ID NO: 74. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides derived from gamma gliadin and / or omega-5-gliadin. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 33, 27527-0242WO1; ISMMS Ref.231101 SEQ ID NO: 34, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, and SEQ ID NO: 57. In some embodiments, each of the wheat peptides comprises a linker for coupling to the solid support, as described herein. In some embodiments, the linker is any of the linkers described herein. In some embodiments, the linker is -PEG12-biotin. In some embodiments, the solid support is a microsphere bead, glass array, silicone array, membrane, or microtiter plate, as described herein. In some embodiments, the AAI is any of the antibodies described herein. In some embodiments, the AAI-specific labeling reagent is any of the detectably labeled antibodies described herein. In some embodiments, the detectable label is any of the detectable labels described herein. In some embodiments, the detection of the binding of the AAI-specific labeling reagent to each AAI-peptide-solid support complex is carried out by a multiplex peptide- bead assay for flow cytometric analysis or a lateral flow assay as described herein. Because the degree of binding of each peptide-specific AAI to the peptide-AAI complex on the solid support can be quantitated, the plurality of peptides selected from among peptides represented by SEQ ID NOs: 1-79 (or any subset thereof described herein) are also useful in methods for detecting an increase in the intensity of wheat allergy over time in a subject diagnosed with wheat allergy or development of wheat allergy over time in a subject initially diagnosed as non-allergic. An initial assay is performed on a plurality of peptides selected from among SEQ ID NOs: 1-79 as described herein (or any subset thereof described herein) to provide an initial number of reactive peptides or an initial concentration of each peptide-specific AAI. At a time-point subsequent to the initial assay, the analysis is repeated with the same plurality of peptides selected from among SEQ ID NOs: 1-79 (or any subset thereof described herein) as the initial profile to obtain a subsequent number of reactive peptides or a subsequent concentration of peptide-specific AAI. This method can be summarized as follows: providing an initial profile of a subject’s serum or plasma AAI reactivity to a plurality of peptides selected from among SEQ ID NOs: 1-79 (or any subset thereof described herein), wherein the initial profile indicates an initial 27527-0242WO1; ISMMS Ref.231101 number of peptides recognized (bound) by AAI in the serum or plasma of the subject or an initial concentration of AAI in the serum or plasma of the subject that recognizes (binds to) each peptide; at a time-point subsequent to the initial profile, contacting each peptide of the same plurality of peptides conjugated to a separately identifiable solid support with serum or plasma from the subject under conditions sufficient to permit binding of AAI in the serum or plasma to the peptide on each solid support, forming a peptide-AAI complex; binding an AAI-specific labeling reagent to the complex, and; analyzing the binding of the labeling reagent to each peptide-AAI complex to identify a subsequent number of peptides recognized by AAI in the serum or plasma of the subject or a subsequent concentration of AAI in the serum or plasma of the subject that reacts with each selected peptide. The methods for detecting an increase in intensity of the allergy may make use of any appropriate assay format, including those described herein. Examples of the types of analyses available for analyzing binding of the labeling reagent are also as described herein. An increase in the number of peptides reactive with AAI at the subsequent time-point compared to the initial profile (including an increase compared to no peptides reactive with AAI in the initial profile), or an increase in intensity of binding of AAI to any of the peptides at the subsequent time-point compared to the initial profile (including an increase from no binding to a particular peptide in the initial profile to detectable binding at the subsequent time-point), indicates an increase in the intensity of wheat allergy in a subject previously diagnosed with wheat allergy or development of wheat allergy in the previously non-allergic subject. As discussed herein, comparing the initial profile of a subject to that of a subsequent time point may be used to predict the subject’s increase in severity or lower tolerance in a particular allergy, or to predict the likelihood of development of clinical or natural tolerance to the allergen. E) Methods of sensitizing an infant The present disclosure also provides methods of sensitizing an infant to one or more wheat allergens to induce tolerance or non-allergy to wheat comprising administering one or more wheat peptides to the infant, wherein the one or more wheat peptides are 27527-0242WO1; ISMMS Ref.231101 derived from low molecular weight glutenin (lmw), alpha / beta gliadin (alb), gamma gliadin (gam), omega-5-gliadin (omg), and / or high molecular weight glutenin (hmw). In some embodiments, each wheat peptide comprises from about from about 6 amino acids to about 30 amino acids, from about 7 amino acids to about 20 amino acids, from about 10 amino acids to about 18 amino acids, or from about 12 amino acids to about 16 amino acids. In some embodiments, each wheat peptide comprises 15 amino acids. In some embodiments, the plurality of wheat peptides comprises at least 2 wheat peptides, at least 3 wheat peptides, at least 5 wheat peptides, at least 10 wheat peptides, at least 15 wheat peptides, at least 20 wheat peptides, or at least 25 wheat peptides. In some embodiments, the plurality of wheat peptides comprises from about 2 to about 25 wheat peptides, from about 2 to about 20 wheat peptides, from about 2 to about 15 wheat peptides, or from about 2 to about 10 wheat peptides. In some embodiments, the plurality of wheat peptides comprises from about 2 to about 25 wheat peptides, from about 3 to about 20 wheat peptides, from about 5 to about 15 wheat peptides, from about 8 to about 15 wheat peptides, from about 10 to about 15 wheat peptides, from about 12 to about 15 wheat peptides, from about 10 to about 14 wheat peptides, or from about 12 to about 14 wheat peptides. In some embodiments, the wheat peptide derived from lmw comprises an amino acid sequence SEQ ID NO: 8. In some embodiments, the one or more wheat peptides derived from alb comprise an amino acid sequence SEQ ID NO: 17 or SEQ ID NO: 20. In some embodiments, the one or more wheat peptides derived from gam comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 43, and SEQ ID NO: 44. In some embodiments, the one or more wheat peptides derived from omg comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, and SEQ ID NO: 57. In some embodiments, the wheat peptide derived from hmw comprises an amino acid sequence SEQ ID NO: 74. 27527-0242WO1; ISMMS Ref.231101 In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 27, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 40, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 62, and SEQ ID NO: 74. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, and SEQ ID NO: 74. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides derived from gamma gliadin and / or omega-5-gliadin. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, and SEQ ID NO: 57. In some embodiments, the age of a subject undergoing administration (e.g., initial administration, any subsequent administration, and / or last administration) can be less than about one year old, less than about 2 years old, less than about 3 years old, less than about 4 years old, less than about 5 years old, or less than about 6 years old. The amount of total peptide or individual peptide can be about 1 gram or less per dose. The administration can be oral, sublingual, intradermal, subcutaneous, inhalation, or epicutaneous. In some embodiments, the initial detection of development of clinical tolerance can be used to predict if a patient will either develop a natural tolerance to the allergy or be responsive to therapy. In some embodiments, an allergic subject is exposed to the immunogen (immunotherapy) prior to analyzing the initial profile. If at the subsequent time-point there is a reduction of at least 2-fold in serum concentration of all AAIs that were highly reactive with peptides in the initial profile, it is likely that the subject will develop either clinical or natural tolerance to wheat. If at the subsequent time-point there is a 27527-0242WO1; ISMMS Ref.231101 reduction of at least 2-fold in serum concentration of fewer than all AAIs that were highly reactive with peptides in the initial profile, the subject is likely to develop only partial clinical or natural tolerance to wheat. The plurality of peptides selected from among peptides represented by SEQ ID NOs: 1-79 (or any subset thereof described herein) are also useful in methods for detecting development of clinical tolerance to wheat proteins in a subject diagnosed with wheat allergy. In some embodiments, the assay generally is as described herein for detection of an increase in allergy intensity, is performed first at an initial time-point to establish an initial profile of serum or plasma AAI reactivity with the plurality of peptides selected from among SEQ ID NOs: 1-79 (or any subset thereof described herein). The initial profile is based on semi-quantitative or quantitative analysis of serum or plasma reactivity with the selected peptides, as discussed herein. The selected peptides conjugated to the solid supports are then contacted with serum or plasma from the subject obtained at a time-point subsequent to the initial profile and the assay is conducted as described herein with semi-quantitation or quantitation of the intensity of wheat allergy at the subsequent time-point. A reduction in the number of peptides reactive with AAI at the subsequent time-point as compared to the initial profile, or a reduction in intensity of binding of AAI to any of the peptides at the subsequent time-point as compared to the initial profile, particularly at least a 2-fold reduction, indicates development of clinical tolerance to wheat proteins. It will be appreciated that development of clinical tolerance to wheat proteins in a subject previously diagnosed with wheat allergy also indicates a decrease in allergy intensity over the time period between the initial profile and the subsequent time-point, and that the method can also be used to detect and predict such decreases in allergy intensity over time. F) Kits The present disclosure also provides kits comprising: a) one or more allergenic epitope-containing wheat peptides derived from low molecular weight glutenin (lmw), alpha / beta gliadin (alb), gamma gliadin (gam), omega-5-gliadin (omg), and / or high molecular weight glutenin (hmw), wherein each wheat peptide is coupled to a solid support; 27527-0242WO1; ISMMS Ref.231101 and b) an allergy associated immunoglobulin (AAI)-specific labeling reagent; packaged together and including instructions for use. In some embodiments, the kits further comprise one or more of a binding buffer, a wash buffer, and a detection buffer. In some embodiments, the kits further comprise a reporter moiety that specifically binds to the AAI-specific labeling reagent. For the convenience of the user, the reagents for use in any of the methods described herein may be packaged together in the form of a kit comprising a plurality of allergenic epitope-containing peptides selected from among the peptides represented by SEQ ID NOs: 1-79 (or any subset thereof described herein), a labeling reagent comprising an anti-human IgE antibody conjugated to a first reporter moiety and, optionally (if required for indirect detection) a second reporter moiety that specifically binds to the labeling reagent. The kit will typically include instructions for use of these reagents in one or more of the methods described herein. In some embodiments, each wheat peptide comprises from about from about 6 amino acids to about 30 amino acids, from about 7 amino acids to about 20 amino acids, from about 10 amino acids to about 18 amino acids, or from about 12 amino acids to about 16 amino acids. In some embodiments, each wheat peptide comprises 15 amino acids. In some embodiments, the plurality of wheat peptides comprises at least 2 wheat peptides, at least 3 wheat peptides, at least 5 wheat peptides, at least 10 wheat peptides, at least 15 wheat peptides, at least 20 wheat peptides, or at least 25 wheat peptides. In some embodiments, the plurality of wheat peptides comprises from about 2 to about 25 wheat peptides, from about 2 to about 20 wheat peptides, from about 2 to about 15 wheat peptides, or from about 2 to about 10 wheat peptides. In some embodiments, the plurality of wheat peptides comprises from about 2 to about 25 wheat peptides, from about 3 to about 20 wheat peptides, from about 5 to about 15 wheat peptides, from about 8 to about 15 wheat peptides, from about 10 to about 15 wheat peptides, from about 12 to about 15 wheat peptides, from about 10 to about 14 wheat peptides, or from about 12 to about 14 wheat peptides. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides derived from lmw comprising an amino acid sequence selected from the 27527-0242WO1; ISMMS Ref.231101 group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, and SEQ ID NO: 13. In some embodiments, the wheat peptide derived from lmw comprises an amino acid sequence SEQ ID NO: 8. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides derived from alb comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, and SEQ ID NO: 26. In some embodiments, the one or more wheat peptides derived from alb comprise an amino acid sequence SEQ ID NO: 17 or SEQ ID NO: 20. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides derived from gam comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, and SEQ ID NO: 45. In some embodiments, the one or more wheat peptides derived from gam comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 27, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 40, SEQ ID NO: 43, and SEQ ID NO: 44. In some embodiments, the one or more wheat peptides derived from gam comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 43, and SEQ ID NO: 44. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides derived from omg comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, and SEQ ID NO: 63. In some embodiments, the one or more wheat peptides derived from omg comprise an amino acid sequence selected from the group consisting of SEQ ID 27527-0242WO1; ISMMS Ref.231101 NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 59, and SEQ ID NO: 62. In some embodiments, the one or more wheat peptides derived from omg comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, and SEQ ID NO: 57. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides derived from hmw comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, and SEQ ID NO: 79. In some embodiments, the wheat peptide derived from hmw comprises an amino acid sequence SEQ ID NO: 74. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 27, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 40, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 62, and SEQ ID NO: 74. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, and SEQ ID NO: 74. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides derived from gamma gliadin and / or omega-5-gliadin. In some embodiments, the plurality of wheat peptides comprises one or more wheat peptides comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, and SEQ ID NO: 57. 27527-0242WO1; ISMMS Ref.231101 In some embodiments, each of the wheat peptides comprises a linker for coupling to the solid support, as described herein. In some embodiments, the linker is any of the linkers described herein. In some embodiments, the linker is -PEG12-biotin. In some embodiments, the solid support is a microsphere bead, glass array, silicone array, membrane, or microtiter plate, as described herein. In some embodiments, the AAI is any of the antibodies described herein. In some embodiments, the AAI-specific labeling reagent is any of the detectably labeled antibodies described herein. In some embodiments, the detectable label is any of the detectable labels described herein. In some embodiments, the detection of the binding of the AAI-specific labeling reagent to each AAI-peptide-solid support complex is carried out by a multiplex peptide- bead assay for flow cytometric analysis or a lateral flow assay as described herein. In some embodiments, the kit may comprise an anti-human AAI antibody that may be provided conjugated to a reporter moiety that can be directly detected. Directly detectable reporter moieties are those that can be identified and / or quantitated without the need for binding to a specific binding partner. Examples of directly-detectable reporter moieties that may be conjugated to the anti-human AAI antibody include fluorescent dyes, colored dyes, chromogenic dyes, and enzyme labels that can be detected by a subsequent chemical reaction, and radiolabels. In some embodiments, the anti-human AAI antibody may be provided conjugated to a reporter moiety that is indirectly detectable, i.e., a reporter moiety that is not itself detectable but which undergoes a reaction or interaction with a second reporter moiety that comprises a directly detectable reporter moiety, such as a specific binding partner for the reporter moiety conjugated to a directly detectable label. Examples of indirectly-detectable reporter moieties include biotin, digoxigenin, and other haptens that are detectable upon subsequent binding of a secondary antibody (e.g., anti- digoxigenin) or other binding partner (e.g., streptavidin) which is labeled for direct detection. It will be understood that any of these labeling reagents and reporter moieties are useful in the appropriate assay format in the methods described herein and as components of the kits. In some embodiments, in a kit for performing the flow cytometry 27527-0242WO1; ISMMS Ref.231101 multiplex assay described herein, the components of the kit may comprise a plurality of allergenic epitope-containing peptides selected from among the peptides represented by SEQ ID NOs: 1-79 (or any subset thereof described herein), a biotinylated anti-human AAI antibody (labeling reagent with first reporter moiety), and streptavidin conjugated to PE (second reporter moiety). The methods described herein can be used as: 1) screening assays (e.g., high-risk patient due to family history of a wheat allergy to inform therapeutic approach / intervention (patient may be exposed to allergen or avoid due to potential severe reaction); patients demonstrating allergy or sensitivity to wheat to guide patients diet and / or likelihood to outgrow (initiation of desensitization the therapy via AIT)); 2) diagnostic assays (e.g., for the diagnosis of a patient with a suspected wheat allergy; to stratify patients based on severity of their allergic response; based on exposure level; based on presentation of the allergen (based on level of allergen protein denaturation); confirm that the reactivity is due to a specific protein within wheat and not a cross reactivity response (report reactivity based on component); 3) predictor assays (e.g., predict therapeutic outcome; determine if a patient will respond to therapy; predict optimal therapeutic approach; predict effective starting dose and / or length of therapy (e.g., 1 year vs.3 years); 4) prognostic assays (e.g., determine if a patient will outgrow their allergy; determine whether allergy will become more severe over time independent of therapy; help characterize the disease to influence treatment decision and guide patient and drug / dose selection); 4) monitoring assays (e.g., adverse event as a result of AIT; and determination of a particular outcome (e.g., desensitization, sustained unresponsiveness, tolerance level, and regression)). Any one or more of these peptides can be conjugated to, for example, a -PEG12- Biotin at its carboxy terminus. In order that the subject matter disclosed herein may be more efficiently understood, examples are provided below. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting the claimed subject matter in any manner. Throughout these examples, molecular cloning reactions, and other standard recombinant DNA techniques, were carried out according to methods described in 27527-0242WO1; ISMMS Ref.231101 Maniatis et al., Molecular Cloning - A Laboratory Manual, 2nd ed., Cold Spring Harbor Press (1989), using commercially available reagents, except where otherwise noted. Examples Example 1: General Methodology Study population: Children and adolescents aged 1-18 years with OFC-confirmed wheat allergy or wheat tolerance were prospectively enrolled from the Division of Allergy and Clinical Immunology, Department of Pediatrics, Siriraj Hospital, Mahidol University, and the Samitivej Allergy Institute, Samitivej Thonburi Hospital, Bangkok, Thailand (SI / SAI). Wheat allergy was defined if they developed objective symptoms compatible with an allergic reaction, whether isolated cutaneous (skin / mucosal involvement) or gastrointestinal symptoms (persistent abdominal pain, vomiting, diarrhea), or anaphylaxis (as defined by the clinical criteria published in the World Allergy Organization guidance of 2020) (Cardona et al., World Allergy Organ J., 2020, 13, 100472). Wheat tolerance was defined if no reaction occurred. Patients who passed the wheat-OFC but developed an allergic reaction during the food-exercise challenge test, or had a negative food-exercise challenge test but a convincing clinical history of exercise-induced wheat-allergic symptoms, and had wheat-sIgE and -5-g- sIgE levels of 0.35 KUA / L, were classified as having WDEIA (Kulthanan et al., J. Allergy Clin. Immunol. Pract., 2022, 10, 2280-96; and Srisuwatchari et al., Asian Pac. J. Allergy Immunol., 2021). Additionally, plasma from 12 subjects with wheat allergy and 18 subjects who were wheat-tolerant was obtained from the Jaffe Food Allergy Institute biorepository at Mount Sinai (FARI). The study was registered on ClinicalTrials.gov (ID: NCT04100122). Library of specific epitope of wheat peptides and the Bead-Based epitope assay (BBEA): The library of wheat epitopes was identified and commercially synthesized byGenScript. It consisted of seventy-nine peptides (15-mer / peptide) from -5-g (Tri a 19), -g(Tri a 20), / -g, (Tri a 21), HMW-glutenin (Tri a 26), and LMW-glutenin (Tri a 36) (see, Table1). Table 1: Library of 79 wheat peptides from 5 wheat proteins 27527-0242WO1; ISMMS Ref.231101 Low molecular weight glutenin (Imw) Peptide label Peptide sequence SEQ ID NO: 27527-0242WO1; ISMMS Ref.231101 alb-14 VSYQQPQQQYPSGQG 24alb-15 QQQYPSGQGSFQPSQ 25 27527-0242WO1; ISMMS Ref.231101 omg-2 PRGKELHTPQEQFPQ 47omg-3 HTPQEQFPQQQQFPQ 48 27527-0242WO1; ISMMS Ref.231101 hmw-20 QSGQGQQPGQGQPGY 73hmw-21 QPGQGQQPGQGQQSG 74 p p y p ., . p., , , ,and all samples were randomized and assayed in duplicate using the PlateDesigner (Suprunet al., Bioinformatics, 2019, 35, 1605-7). Briefly, peptides were coupled to LumAvidin beads and a master mix of avidin bead-coupled peptides was stored in BBEA buffer (1xPBS +0.1%BSA + 0.02%Tween-20). The master mix was then added to 96-well filter plates (100 Lor 1000 beads / well) and after washing, 1:10 dilutions (100 L / well) of individualplasma / serum samples were added and incubated for 2 hours. Plates were washed andincubated for another 30 minutes with 50 L / well of mouse antihuman IgE (1:50 dilution),IgG4 (1:1,000 dilution), or IgG1 (1:10,000 dilution) (Thermo-Fisher Scientific, Waltham,Mass). After a final wash, beads were resuspended in 100 µL / well of buffer and transferred to fixed-bottom 96-well plates. A Luminex200 (Luminex Corporation) spectrophotometer was used to analyze the median fluorescence intensity. Predictive modeling using machine learning methods: Machine learning (ML) methods were used to identify diagnostic epitopes and performance against wheat-sIgE and wheat SPT. BORUTA served as the feature selection method in this study. This algorithm rigorously evaluated the importance of each feature by using simulation techniques to generate ‘shadow features’. These shadow features are randomly shuffled copies of all features, representing the null distribution of importance. In each iteration, a Random Forrest classifier is trained, and the importance (as Mean Decrease Accuracy) is measured. This is performed by comparing it against the distribution 27527-0242WO1; ISMMS Ref.231101 of the shadow features and testing against the null. Epitopes with significantly lower importance than the shadow features are rejected, while those with significant importance are affirmed as ‘Confirmed’. The algorithm concludes either when only ‘Confirmed’ attributes remain or when a predetermined maximum number of iterations is reached. In the latter scenario, attributes that remain indecisive are classified as ‘Tentative’. Epitopes classified as ‘Confirmed’ or ‘Tentative’ were considered for analysis. In this study, the significance threshold for feature selection was set at a BORUTA Bonferroni-adjusted p- value of 0.01. This threshold was determined over the course of 99 simulations to ensure a robust and reliable process. This iterative method allows BORUTA to effectively distinguish between truly informative features and those that are no more predictive than random noise (i.e., null), thereby enhancing the accuracy of wheat allergy prediction through more relevant epitope identification. Statistical analysis: Statistical analyses were performed using R Statistics version 4.2.2. Categorical data are presented as numbers and percentages and were analyzed by Chi-squared or Fisher’s exact test, as appropriate. Continuous data were expressed as mean ± SD if normally- distributed or median and interquartile range (IQR) if non-normally distributed and were analyzed using Mann-Whitney and Kruskal-Wallis tests. The index score of binding intensity of epitope-specific antibody was calculated from the log2 transformation of the signal-to-background ratio and each wheat peptide. A plate effect was adjusted for using linear models (see, Figure 5). Comparisons of es-IgE, es- IgG4, and es-IgG1 antibodies binding intensities were performed between the groups and analyzed using t-tests and resultant P-values were adjusted for multiple hypotheses using the Benjamini-Hochberg approach, which controls the false discovery rate (FDR) across epitopes. Epitopes were defined as differentially binding epitopes (DBE) if the FDR < 0.05 and fold changes (FCH) > 1.5. A multivariable logistic regression model with logit link function was performed using combinations of up to 4 epitopes. Performance metrics (i.e., AUC, sensitivity, specificity, NPV, and PPV) were estimated for all models in the cross-validated, training and 27527-0242WO1; ISMMS Ref.231101 testing datasets. The Youden index was used for the decision threshold such that patients above that level of reactivity were defined as allergic. BBEA models were compared with wheat-sIgE and SPT using ROC curves for the training set. The performance of the optimal model was then evaluated using an external sub-cohort from the Mount Sinai FARI cohort. Example 2: Wheat Study Results Study participants: A total of 114 children were included for the analysis, 80 were classified as wheat- allergic and 34 were wheat-tolerant. Characteristics of the study participants are shown in Table 2 and Table 3. Table 2: Demographic and clinical characteristics compared between wheat allergic and wheat tolerant patients (N=114) Characteristics Wheat-allergicWheat-tolerant p 27527-0242WO1; ISMMS Ref.231101 Other allergic diseases A p-value<0.05 indicates sta s cal signi cance; CoFARV3 grade 3-5; Abbreviations: mo,months; yrs, years Table 3: Demographic and clinical characteristics compared between wheat-allergic (anaphylaxis, isolated cutaneous symptoms, wheat dependent exercise-induced anaphylaxis)* and wheat-tolerant patients Characteristics AnaphylaxisIsolated WDEIA Wheat p 27527-0242WO1; ISMMS Ref.231101 Age at onset7.6 ± 3.6 17.1 ± 29.9 128.2 ± 37.9 25.4 ± 39.7 <0.001(mo) mean ± 27527-0242WO1; ISMMS Ref.231101 Data presented as number and percentage or mean and standard deviation (SD) or median and interquartile range (IQR); A p-value<0.05 indicates statistical significance; *Excluded 12 wheat-allergic patients from FARI, and 1 patient from SI / SAI with isolated gastrointestinalsymptoms; † 21 pa ents from SI / SAI, and 18 pa ents from FARI; CoFARV3 grade 3-5;Abbreviations: mo, months; yrs, years; WDEIA, wheat dependent exercise-induced anaphylaxis The mean age at enrollment was 7.34 4.12 years, and X% of them were male.Median level of wheat-sIgE in wheat-allergic patients was significantly higher than wheat-tolerant group (12.5 kU / L [IQR 2.05-89.30] vs.4.16 kU / L [IQR0.81-20.67], p=0.021).BBEA for es-IgE, es-IgG4, and es-IgG1 binding to wheat peptides compared between wheat- allergic and wheat-tolerant subjects: There was a significant difference in es-IgE binding intensity, expressed as FCH, inalmost all individual wheat epitopes. However, there was not a significant difference observed in es-IgG4 and es-IgG1 between wheat-allergic and wheat-tolerant children (data not shown). When analyzing diversity binding for five wheat peptides compared between the two groups, wheat allergic patients showed significantly higher es-IgE binding across allwheat peptides, with the highest difference in -5-gliadin and -gliadin, but no differencesin es-IgG4, and es-IgG1 (see, Figure 1, Panels A, B, and C). Similar results were also foundwhen analyzing the average binding of es-IgE, es-IgG4, and es-IgG1 to all wheat peptides (see, Figure 6). BBEA for es-IgE, es-IgG4, and es-IgG1 binding to wheat peptides to differentiate the wheat allergy phenotype: An analysis of binding diversity for each wheat allergy clinical phenotype compared to the wheat-tolerant for es-IgE, es-IgG4 and es-IgG1 is shown in Figure 2, Panels A, B, and C. Es-IgE expansion correlated with allergy severity, showing higher binding and diversity in anaphylactic subjects followed by those with cutaneous symptoms only. The latter groupexhibited differences from the wheat-tolerant group mainly in -5-gliadin and -gliadin. In 27527-0242WO1; ISMMS Ref.231101 contrast, WDEIA es-IgE binding was similar to that in wheat-tolerant patients, but es-IgG4 and es-IgG1 binding across all epitopes was significantly less than in all other groups. Similar results were observed in the average binding analysis of es-IgE, es-IgG4, and es-IgG1 forwheat peptides (see, Figure 7).Prediction of reactivity to wheat, based on the accuracy of wheat es-IgE, es-IgG4, and es- IgG1 antibodies: Figure 3A and Figure 8 illustrate the mean importance of each epitope for es-IgE, es-IgG4, and es-IgG1. The overall results suggest that both es-IgE and es-IgG4 contain epitopes important for predicting wheat allergy status. However, es-IgE epitopes aresignificantly more important than es-IgG4 and es-IgG1, particularly to -5-gliadin, -gliadin, / -gliadin in predicting wheat allergy (see, Figure 3, Panels B and C, and Figure 9).Individual es-IgE levels for the most predictive epitopes are presented as boxplots, showing their importance across simulations (see, Figure 3, Panel D). Additionally, the AUC results from a 10-fold cross-validation after univariate logistic regression analysis is shown inFigure 3, Panel E. Overall, -5-gliadin and -gliadin emerge as the most informativepredictive epitopes. The AUCs of the top 10 models for IgE, comparing average IgE and plate-adjusted average IgE across 10-fold cross-validation, training and testing datasets are presented. Plate adjustment did not enhance model performance but demonstrated comparable results to average IgE, which consistently exhibited higher AUC values across datasets (see, Figure 10). The distribution of 10-fold cross-validation AUCs for model combinations illustrated the utility of progressively adding additional important epitopes to models with up to 4 unique epitopes. Significant differences in average AUCs were observed up until quadrivariate models, indicating diminishing returns on adding a fifth epitope (see, Figure 11). Figure 4, Panels A and B, display ROC curves comparing the top four BBEA model accuracy in the training data based on es-IgE-binding with models using wheat-sIgE or wheat SPT. The predictive ability of BBEA for es-IgE was superior across all models, achieving the highest AUC of 0.90 (sensitivity=89%, specificity=81%). This performance was 27527-0242WO1; ISMMS Ref.231101 significantly superior to that of wheat-sIgE >5.18 kUA / L (AUC of 0.90; sensitivity=98%, specificity=7%) or the wheat SPT>4.7 mm (AUC of 0.81; sensitivity=86%, specificity=48%) (see, Figure 4, Panels A and B). The comparison of allergy scores between wheat BBEA and wheat-sIgE is presented in Figure 4, Panel C. Dark lines represent the allergy threshold for each model (wheat-sIgE dashed horizontal line, BBEA solid vertical line). Points above and to the right of thresholds deemed allergic, and those below are not allergic. The top two models are illustrated, demonstrating high discrimination in the training set with 12 misclassifications betweenBBEA model’s 1 and 2. Each model utilizes a unique combination of -5-g and -g.Various modifications of the described subject matter, in addition to those described herein, will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference (including, but not limited to, journal articles, U.S. and non-U.S. patents, patent application publications, international patent application publications, gene bank accession numbers, and the like) cited in the present application is incorporated herein by reference in its entirety.

Claims

27527-0242WO1; ISMMS Ref.231101 What Is Claimed Is:

1. A method for diagnosing a wheat allergy, and / or severity of a wheat allergy, in asubject comprising: contacting one or more wheat peptides with serum or plasma obtained from the subject under conditions sufficient to permit binding of one or more allergy associated immunoglobulins (AAIs) in the serum or plasma to the one or more wheat peptides, wherein the one or more wheat peptides are coupled to a solid support, to form one or more AAI-peptide-solid support complexes; binding an AAI-specific labeling reagent to the AAI-peptide-solid support complex; and detecting binding of the AAI-specific labeling reagent to each AAI-peptide-solid support complex to identify one or more wheat peptides bound to the AAI in the serum or plasma of the subject; wherein recognition of at least one wheat peptide by an AAI in the serum or plasma of the subject indicates that the subject is allergic to wheat, and wherein the greater the number of wheat peptides recognized and / or the greater the level of wheat peptide binding the more severe the wheat allergy.

2. The method of claim 1, wherein each wheat peptide comprises from about fromabout 6 amino acids to about 30 amino acids, from about 7 amino acids to about 20 amino acids, from about 10 amino acids to about 18 amino acids, or from about 12 amino acids to about 16 amino acids.

3. The method of claim 1, wherein each wheat peptide comprises 15 amino acids.

4. The method of any one of claims 1 to 3, wherein the one or more wheat peptidescomprise at least 2 wheat peptides, at least 3 wheat peptides, at least 5 wheat peptides, at least 10 wheat peptides, at least 15 wheat peptides, at least 20 wheat peptides, or at least 25 what peptides.27527-0242WO1; ISMMS Ref.2311015. The method of any one of claims 1 to 4, wherein the one or more wheat peptides isderived from low molecular weight glutenin (lmw), alpha / beta gliadin (alb), gamma gliadin (gam), omega-5-gliadin (omg), and / or high molecular weight glutenin (hmw).

6. The method of claim 5, wherein the one or more wheat peptides derived from lmwcomprise an amino acid sequence selected from the group consisting of ENSHIPGLERPSQQQ (SEQ ID NO: 1), HIPGLERPSQQQPLP (SEQ ID NO: 2), RPSQQQPLPPQQTLS (SEQ ID NO: 3), QQQPIQQQPQPFSQQ (SEQ ID NO: 4), PIQQQPQPFSQQQPC (SEQ ID NO: 5), QQQPLSQQQQPPFSQ (SEQ ID NO: 6), QQQQPPFSQQQPPFS (SEQ ID NO: 7), LSQQQQPPFSQQQPP (SEQ ID NO: 8), FSQQQQPPFSQQQPP (SEQ ID NO: 9), FSQQQQPVLPQQPSF (SEQ ID NO: 10), GSIQTPQQQPQQLGQ (SEQ ID NO: 11), QPQQQSQQQLGQQPQ (SEQ ID NO: 12), and QQQLGQQPQQQQLAQ (SEQ ID NO: 13).

7. The method of claim 6, wherein the wheat peptide derived from lmw comprises anamino acid sequence LSQQQQPPFSQQQPP (SEQ ID NO: 8).

8. The method of claim 5, wherein the one or more wheat peptides derived from albcomprise an amino acid sequence selected from the group consisting of PVPQLQPQNPSQQQP (SEQ ID NO: 14), PQNPSQQQPQEQVPL (SEQ ID NO: 15), LGQQQQHFPGQQQPF (SEQ ID NO: 16), GQQQPFPPQQPYPQP (SEQ ID NO: 17), QPFPPQQPYPQPQPF (SEQ ID NO: 18), LPYPQPQPFPPQQSY (SEQ ID NO: 19), QPFPPQQSYPQPQPQ (SEQ ID NO: 20), QPQYPQPQQPISQQQ (SEQ ID NO: 21), SSQVSQQSYQLLQQL (SEQ ID NO: 22), QQPSSQVSYQQPQQQ (SEQ ID NO: 23), VSYQQPQQQYPSGQG (SEQ ID NO: 24), QQQYPSGQGSFQPSQ (SEQ ID NO: 25), and QLPQFEEIRNLALQT (SEQ ID NO: 26).

9. The method of claim 8, wherein the one or more wheat peptides derived from albcomprise an amino acid sequence GQQQPFPPQQPYPQP (SEQ ID NO: 17) or QPFPPQQSYPQPQPQ (SEQ ID NO: 20).27527-0242WO1; ISMMS Ref.23110110. The method of claim 5, wherein the one or more wheat peptides derived from gamcomprise an amino acid sequence selected from the group consisting of LTILAMAITIGTANM (SEQ ID NO: 27), WPQQQPVPQPHQPFS (SEQ ID NO: 28), VPQPHQPFSQQPQQT (SEQ ID NO: 29), PFSQQPQQTFPQPQQ (SEQ ID NO: 30), FPQPQQTFPHQPQQQ (SEQ ID NO: 31), TFPHQPQQQFPQPQQ (SEQ ID NO: 32), QQQFPQPQQPQQQFL (SEQ ID NO: 33), QPQQPFPQQPQQPYP (SEQ ID NO: 34), PQQPYPQQPQQPFPQ (SEQ ID NO: 35), QQPFPQTQQPQQLFP (SEQ ID NO: 36), LFPQSQQPQQQFSQP (SEQ ID NO: 37), QPQQQFSQPQQQFPQ (SEQ ID NO: 38), FPQPQQPQQSFPQQQ (SEQ ID NO: 39), PQQSFPQQQPPFIQP (SEQ ID NO: 40), IMQQEQQEQQQGMHI (SEQ ID NO: 41), VQGQGIIQPQQPAQL (SEQ ID NO: 42), PQQPFPQPQQTFPQQ (SEQ ID NO: 43), PFPQQPQQPFPQPQQ (SEQ ID NO: 44), and IQSFLQQQMNPCKNF (SEQ ID NO: 45).

11. The method of claim 10, wherein the one or more wheat peptides derived fromgam comprise an amino acid sequence selected from the group consisting of LTILAMAITIGTANM (SEQ ID NO: 27), PFSQQPQQTFPQPQQ (SEQ ID NO: 30), FPQPQQTFPHQPQQQ (SEQ ID NO: 31), TFPHQPQQQFPQPQQ (SEQ ID NO: 32), QQQFPQPQQPQQQFL (SEQ ID NO: 33), QPQQPFPQQPQQPYP (SEQ ID NO: 34), PQQPYPQQPQQPFPQ (SEQ ID NO: 35), PQQSFPQQQPPFIQP (SEQ ID NO: 40), PQQPFPQPQQTFPQQ (SEQ ID NO: 43), and PFPQQPQQPFPQPQQ (SEQ ID NO: 44).

12. The method of claim 10, wherein the one or more wheat peptides derived fromgam comprise an amino acid sequence selected from the group consisting of QQQFPQPQQPQQQFL (SEQ ID NO: 33), QPQQPFPQQPQQPYP (SEQ ID NO: 34), PQQPFPQPQQTFPQQ (SEQ ID NO: 43), and PFPQQPQQPFPQPQQ (SEQ ID NO: 44).

13. The method of claim 5, wherein the one or more wheat peptides derived from omgcomprise an amino acid sequence selected from the group consisting of AMNIASASRLLSPRG (SEQ ID NO: 46), PRGKELHTPQEQFPQ (SEQ ID NO: 47), HTPQEQFPQQQQFPQ (SEQ ID NO: 48), PQQFPQQQQFPQQHQ (SEQ ID NO: 49), QQIPQQPQQFLQQQQ (SEQ ID NO: 50),27527-0242WO1; ISMMS Ref.231101 FPQQQSPQQQQFPQQ (SEQ ID NO: 51), FPQQQEFPQQQFPQQ (SEQ ID NO: 52), QQFPRPQQSPEQQQF (SEQ ID NO: 53), PEQQQFPQQQFPQQP (SEQ ID NO: 54), QQSFSYQQQPFPQQP (SEQ ID NO: 55), QQQPFPQQPYPQQPY (SEQ ID NO: 56), QPQQPFPQQPQQPQQ (SEQ ID NO: 57), QPFPQQPQQPQQPFP (SEQ ID NO: 58), PFPQPQQPFPWQPQQ (SEQ ID NO: 59), QFQESIKHKSKMKTF (SEQ ID NO: 60), QQRFPHTRQKFPRNP (SEQ ID NO: 61), STHHFPAQQPFPQQP (SEQ ID NO: 62), and PFPQQPGQIIPQQPQ (SEQ ID NO: 63).

14. The method of claim 13, wherein the one or more wheat peptides derived fromomg comprise an amino acid sequence selected from the group consisting of PQQFPQQQQFPQQHQ (SEQ ID NO: 49), FPQQQEFPQQQFPQQ (SEQ ID NO: 52), PEQQQFPQQQFPQQP (SEQ ID NO: 54), QQSFSYQQQPFPQQP (SEQ ID NO: 55), QQQPFPQQPYPQQPY (SEQ ID NO: 56), QPQQPFPQQPQQPQQ (SEQ ID NO: 57), PFPQPQQPFPWQPQQ (SEQ ID NO: 59), and STHHFPAQQPFPQQP (SEQ ID NO: 62).

15. The method of claim 13, wherein the one or more wheat peptides derived fromomg comprise an amino acid sequence selected from the group consisting of PQQFPQQQQFPQQHQ (SEQ ID NO: 49), FPQQQEFPQQQFPQQ (SEQ ID NO: 52), PEQQQFPQQQFPQQP (SEQ ID NO: 54), QQSFSYQQQPFPQQP (SEQ ID NO: 55), QQQPFPQQPYPQQPY (SEQ ID NO: 56), and QPQQPFPQQPQQPQQ (SEQ ID NO: 57).

16. The method of claim 5, wherein the one or more wheat peptides derived fromhmw comprise an amino acid sequence selected from the group consisting of SPQRPGQGQQPGQGQ (SEQ ID NO: 64), QGQQPGQGQQGQQPG (SEQ ID NO: 65), QQPGQGQQPGQLQQP (SEQ ID NO: 66), QQPAQGQQGQQPGQG (SEQ ID NO: 67), QLQQMIFWGIPALLR (SEQ ID NO: 68), ASPQQSGQGQQPGQE (SEQ ID NO: 69), GQGQQPGQEQQPGQG (SEQ ID NO: 70), QQPGQGQQDQQPGQR (SEQ ID NO: 71), QPGQKQQAGQGQQSG (SEQ ID NO: 72), QSGQGQQPGQGQPGY (SEQ ID NO: 73), QPGQGQQPGQGQQSG (SEQ ID NO: 74), SLRQPGQWQQPGQGQ (SEQ ID NO: 75), PQQSGQGQQLGQGQP (SEQ ID NO: 76), GQQPAQGQQSAQEQQ (SEQ ID NO: 77),27527-0242WO1; ISMMS Ref.231101 PQQSGQGQQPGHEQQ (SEQ ID NO: 78), and EQQPGQWLQPGQGQQ (SEQ ID NO: 79).

17. The method of claim 16, wherein the wheat peptide derived from hmw comprisesan amino acid sequence QPGQGQQPGQGQQSG (SEQ ID NO: 74).

18. The method of claim 5, wherein the one or more wheat peptides comprise anamino acid sequence selected from the group consisting of LSQQQQPPFSQQQPP (SEQ ID NO: 8), GQQQPFPPQQPYPQP (SEQ ID NO: 17), QPFPPQQSYPQPQPQ (SEQ ID NO: 20), LTILAMAITIGTANM (SEQ ID NO: 27), PFSQQPQQTFPQPQQ (SEQ ID NO: 30), FPQPQQTFPHQPQQQ (SEQ ID NO: 31), TFPHQPQQQFPQPQQ (SEQ ID NO: 32), QQQFPQPQQPQQQFL (SEQ ID NO: 33), QPQQPFPQQPQQPYP (SEQ ID NO: 34), PQQPYPQQPQQPFPQ (SEQ ID NO: 35), PQQSFPQQQPPFIQP (SEQ ID NO: 40), PQQPFPQPQQTFPQQ (SEQ ID NO: 43), PFPQQPQQPFPQPQQ (SEQ ID NO: 44), PQQFPQQQQFPQQHQ (SEQ ID NO: 49), FPQQQEFPQQQFPQQ (SEQ ID NO: 52), PEQQQFPQQQFPQQP (SEQ ID NO: 54), QQSFSYQQQPFPQQP (SEQ ID NO: 55), QQQPFPQQPYPQQPY (SEQ ID NO: 56), QPQQPFPQQPQQPQQ (SEQ ID NO: 57), PFPQPQQPFPWQPQQ (SEQ ID NO: 59), STHHFPAQQPFPQQP (SEQ ID NO: 62), and QPGQGQQPGQGQQSG (SEQ ID NO: 74).

19. The method of claim 5, wherein the one or more wheat peptides comprise anamino acid sequence selected from the group consisting of LSQQQQPPFSQQQPP (SEQ ID NO: 8), GQQQPFPPQQPYPQP (SEQ ID NO: 17), QPFPPQQSYPQPQPQ (SEQ ID NO: 20), QQQFPQPQQPQQQFL (SEQ ID NO: 33), QPQQPFPQQPQQPYP (SEQ ID NO: 34), PQQPFPQPQQTFPQQ (SEQ ID NO: 43), PFPQQPQQPFPQPQQ (SEQ ID NO: 44), PQQFPQQQQFPQQHQ (SEQ ID NO: 49), FPQQQEFPQQQFPQQ (SEQ ID NO: 52), PEQQQFPQQQFPQQP (SEQ ID NO: 54), QQSFSYQQQPFPQQP (SEQ ID NO: 55), QQQPFPQQPYPQQPY (SEQ ID NO: 56), QPQQPFPQQPQQPQQ (SEQ ID NO: 57), and QPGQGQQPGQGQQSG (SEQ ID NO: 74).27527-0242WO1; ISMMS Ref.23110120. The method of any one of claims 1 to 4, wherein the one or more wheat peptides isderived from gamma gliadin (gam) and / or omega-5-gliadin (omg).

21. The method of claim 20, wherein the one or more wheat peptides comprise anamino acid sequence selected from the group consisting of QQQFPQPQQPQQQFL (SEQ ID NO: 33), QPQQPFPQQPQQPYP (SEQ ID NO: 34), PQQPFPQPQQTFPQQ (SEQ ID NO: 43), PFPQQPQQPFPQPQQ (SEQ ID NO: 44), PQQFPQQQQFPQQHQ (SEQ ID NO: 49), FPQQQEFPQQQFPQQ (SEQ ID NO: 52), PEQQQFPQQQFPQQP (SEQ ID NO: 54), QQSFSYQQQPFPQQP (SEQ ID NO: 55), QQQPFPQQPYPQQPY (SEQ ID NO: 56), and QPQQPFPQQPQQPQQ (SEQ ID NO: 57).

22. The method of any one of claims 1 to 21, wherein each of the wheat peptidescomprises a linker for coupling to the solid support.

23. The method of claim 22, wherein the linker is -PEG12-biotin.

24. The method of any one of claims 1 to 23, wherein the solid support is amicrosphere bead, glass array, silicone array, membrane, or microtiter plate.

25. The method of any one of claims 1 to 24, wherein the AAI is IgG and / or IgE.

26. The method of claim 25, wherein the IgG is IgG4.

27. The method of any one of claims 1 to 26, wherein the AAI-specific labeling reagentis a detectably labeled anti-human IgG antibody and / or a detectably labeled anti-human IgE antibody.

28. The method of claim 27, wherein the detectable label is phycoerythrin, afluorescent dye, horse radish peroxidase (HRP), or alkaline phosphatase.27527-0242WO1; ISMMS Ref.23110129. The method of any one of claims 1 to 28, wherein the detection of the binding ofthe AAI-specific labeling reagent to each AAI-peptide-solid support complex is carried out by a multiplex peptide-bead assay for flow cytometric analysis or a lateral flow assay.

30. A method for detecting development of clinical tolerance to wheat in a subject thatis allergic to wheat comprising: contacting one or more wheat peptides with serum or plasma obtained from the subject under conditions sufficient to permit binding of one or more allergy associated immunoglobulins (AAIs) in the serum or plasma to the one or more wheat peptides, wherein the one or more wheat peptides are coupled to a solid support, to form one or more AAI-peptide-solid support complexes; binding an AAI-specific labeling reagent to the AAI-peptide-solid support complex; detecting binding of the AAI-specific labeling reagent to each AAI-peptide-solid support complex to identify one or more wheat peptides bound to the AAI in the serum or plasma of the subject; and comparing the identified one or more wheat peptides bound to the AAI in the serum or plasma of the subject, or the concentration of the AAI in the serum or plasma of the subject, with a previously identified panel of one or more wheat peptides bound to the AAI in the serum or plasma of the subject, or a previous concentration of the AAI in the serum or plasma of the subject; wherein development of clinical tolerance to wheat is indicated when: the subsequent number of wheat peptides recognized by IgE AAI in the serum or plasma of the subject, and / or the subsequent concentration of AAI IgE in the serum or plasma of the subject, is less than the previously identified number of wheat peptides recognized by AAI IgE in the serum or plasma of the subject, and / or less than the previous concentration of AAI IgE in the serum or plasma of the subject; and / or the subsequent number of wheat peptides recognized by IgG4 AAI in the serum or plasma of the subject, and / or the subsequent concentration of AAI IgG4 in the serum or plasma of the subject, is greater than the previously identified27527-0242WO1; ISMMS Ref.231101 number of wheat peptides recognized by AAI IgG4 in the serum or plasma of the subject, and / or greater than the previous concentration of AAI IgG4 in the serum or plasma of the subject.

31. The method of claim 30, wherein each wheat peptide comprises from about fromabout 6 amino acids to about 30 amino acids, from about 7 amino acids to about 20 amino acids, from about 10 amino acids to about 18 amino acids, or from about 12 amino acids to about 16 amino acids.

32. The method of claim 30, wherein each wheat peptide comprises 15 amino acids.

33. The method of any one of claims 30 to 32, wherein the one or more wheatpeptides comprise at least 2 wheat peptides, at least 3 wheat peptides, at least 5 wheat peptides, at least 10 wheat peptides, at least 15 wheat peptides, at least 20 wheat peptides, or at least 25 what peptides.

34. The method of any one of claims 30 to 33, wherein the one or more wheatpeptides is derived from low molecular weight glutenin (lmw), alpha / beta gliadin (alb), gamma gliadin (gam), omega-5-gliadin (omg), and / or high molecular weight glutenin (hmw).

35. The method of claim 34, wherein the one or more wheat peptides derived fromlmw comprise an amino acid sequence selected from the group consisting of ENSHIPGLERPSQQQ (SEQ ID NO: 1), HIPGLERPSQQQPLP (SEQ ID NO: 2), RPSQQQPLPPQQTLS(SEQ ID NO: 3), QQQPIQQQPQPFSQQ (SEQ ID NO: 4), PIQQQPQPFSQQQPC (SEQ IDNO: 5), QQQPLSQQQQPPFSQ (SEQ ID NO: 6), QQQQPPFSQQQPPFS (SEQ ID NO: 7), LSQQQQPPFSQQQPP (SEQ ID NO: 8), FSQQQQPPFSQQQPP (SEQ ID NO: 9), FSQQQQPVLPQQPSF (SEQ ID NO: 10), GSIQTPQQQPQQLGQ (SEQ ID NO: 11), QPQQQSQQQLGQQPQ (SEQ ID NO: 12), and QQQLGQQPQQQQLAQ (SEQ ID NO: 13).27527-0242WO1; ISMMS Ref.23110136. The method of claim 35, wherein the wheat peptide derived from lmw comprisesan amino acid sequence LSQQQQPPFSQQQPP (SEQ ID NO: 8).

37. The method of claim 34, wherein the one or more wheat peptides derived from albcomprise an amino acid sequence selected from the group consisting of PVPQLQPQNPSQQQP (SEQ ID NO: 14), PQNPSQQQPQEQVPL (SEQ ID NO: 15), LGQQQQHFPGQQQPF (SEQ ID NO: 16), GQQQPFPPQQPYPQP (SEQ ID NO: 17), QPFPPQQPYPQPQPF (SEQ ID NO: 18), LPYPQPQPFPPQQSY (SEQ ID NO: 19), QPFPPQQSYPQPQPQ (SEQ ID NO: 20), QPQYPQPQQPISQQQ (SEQ ID NO: 21), SSQVSQQSYQLLQQL (SEQ ID NO: 22), QQPSSQVSYQQPQQQ (SEQ ID NO: 23), VSYQQPQQQYPSGQG (SEQ ID NO: 24), QQQYPSGQGSFQPSQ (SEQ ID NO: 25), and QLPQFEEIRNLALQT (SEQ ID NO: 26).

38. The method of claim 37, wherein the one or more wheat peptides derived from albcomprise an amino acid sequence GQQQPFPPQQPYPQP (SEQ ID NO: 17) or QPFPPQQSYPQPQPQ (SEQ ID NO: 20).

39. The method of claim 34, wherein the one or more wheat peptides derived fromgam comprise an amino acid sequence selected from the group consisting of LTILAMAITIGTANM (SEQ ID NO: 27), WPQQQPVPQPHQPFS (SEQ ID NO: 28), VPQPHQPFSQQPQQT (SEQ ID NO: 29), PFSQQPQQTFPQPQQ (SEQ ID NO: 30), FPQPQQTFPHQPQQQ (SEQ ID NO: 31), TFPHQPQQQFPQPQQ (SEQ ID NO: 32), QQQFPQPQQPQQQFL (SEQ ID NO: 33), QPQQPFPQQPQQPYP (SEQ ID NO: 34), PQQPYPQQPQQPFPQ (SEQ ID NO: 35), QQPFPQTQQPQQLFP (SEQ ID NO: 36), LFPQSQQPQQQFSQP (SEQ ID NO: 37), QPQQQFSQPQQQFPQ (SEQ ID NO: 38), FPQPQQPQQSFPQQQ (SEQ ID NO: 39), PQQSFPQQQPPFIQP (SEQ ID NO: 40), IMQQEQQEQQQGMHI (SEQ ID NO: 41), VQGQGIIQPQQPAQL (SEQ ID NO: 42), PQQPFPQPQQTFPQQ (SEQ ID NO: 43), PFPQQPQQPFPQPQQ (SEQ ID NO: 44), and IQSFLQQQMNPCKNF (SEQ ID NO: 45).27527-0242WO1; ISMMS Ref.23110140. The method of claim 39, wherein the one or more wheat peptides derived fromgam comprise an amino acid sequence selected from the group consisting of LTILAMAITIGTANM (SEQ ID NO: 27), PFSQQPQQTFPQPQQ (SEQ ID NO: 30), FPQPQQTFPHQPQQQ (SEQ ID NO: 31), TFPHQPQQQFPQPQQ (SEQ ID NO: 32), QQQFPQPQQPQQQFL (SEQ ID NO: 33), QPQQPFPQQPQQPYP (SEQ ID NO: 34), PQQPYPQQPQQPFPQ (SEQ ID NO: 35), PQQSFPQQQPPFIQP (SEQ ID NO: 40), PQQPFPQPQQTFPQQ (SEQ ID NO: 43), and PFPQQPQQPFPQPQQ (SEQ ID NO: 44).

41. The method of claim 39, wherein the one or more wheat peptides derived fromgam comprise an amino acid sequence selected from the group consisting of QQQFPQPQQPQQQFL (SEQ ID NO: 33), QPQQPFPQQPQQPYP (SEQ ID NO: 34), PQQPFPQPQQTFPQQ (SEQ ID NO: 43), and PFPQQPQQPFPQPQQ (SEQ ID NO: 44).

42. The method of claim 34, wherein the one or more wheat peptides derived fromomg comprise an amino acid sequence selected from the group consisting of AMNIASASRLLSPRG (SEQ ID NO: 46), PRGKELHTPQEQFPQ (SEQ ID NO: 47), HTPQEQFPQQQQFPQ (SEQ ID NO: 48), PQQFPQQQQFPQQHQ (SEQ ID NO: 49), QQIPQQPQQFLQQQQ (SEQ ID NO: 50), FPQQQSPQQQQFPQQ (SEQ ID NO: 51), FPQQQEFPQQQFPQQ (SEQ ID NO: 52), QQFPRPQQSPEQQQF (SEQ ID NO: 53), PEQQQFPQQQFPQQP (SEQ ID NO: 54), QQSFSYQQQPFPQQP (SEQ ID NO: 55), QQQPFPQQPYPQQPY (SEQ ID NO: 56), QPQQPFPQQPQQPQQ (SEQ ID NO: 57), QPFPQQPQQPQQPFP (SEQ ID NO: 58), PFPQPQQPFPWQPQQ (SEQ ID NO: 59), QFQESIKHKSKMKTF (SEQ ID NO: 60), QQRFPHTRQKFPRNP (SEQ ID NO: 61), STHHFPAQQPFPQQP (SEQ ID NO: 62), and PFPQQPGQIIPQQPQ (SEQ ID NO: 63).

43. The method of claim 42, wherein the one or more wheat peptides derived fromomg comprise an amino acid sequence selected from the group consisting of PQQFPQQQQFPQQHQ (SEQ ID NO: 49), FPQQQEFPQQQFPQQ (SEQ ID NO: 52),27527-0242WO1; ISMMS Ref.231101 PEQQQFPQQQFPQQP (SEQ ID NO: 54), QQSFSYQQQPFPQQP (SEQ ID NO: 55), QQQPFPQQPYPQQPY (SEQ ID NO: 56), QPQQPFPQQPQQPQQ (SEQ ID NO: 57), PFPQPQQPFPWQPQQ (SEQ ID NO: 59), and STHHFPAQQPFPQQP (SEQ ID NO: 62).

44. The method of claim 42, wherein the one or more wheat peptides derived fromomg comprise an amino acid sequence selected from the group consisting of PQQFPQQQQFPQQHQ (SEQ ID NO: 49), FPQQQEFPQQQFPQQ (SEQ ID NO: 52), PEQQQFPQQQFPQQP (SEQ ID NO: 54), QQSFSYQQQPFPQQP (SEQ ID NO: 55), QQQPFPQQPYPQQPY (SEQ ID NO: 56), and QPQQPFPQQPQQPQQ (SEQ ID NO: 57).

45. The method of claim 34, wherein the one or more wheat peptides derived fromhmw comprise an amino acid sequence selected from the group consisting of SPQRPGQGQQPGQGQ (SEQ ID NO: 64), QGQQPGQGQQGQQPG (SEQ ID NO: 65), QQPGQGQQPGQLQQP (SEQ ID NO: 66), QQPAQGQQGQQPGQG (SEQ ID NO: 67), QLQQMIFWGIPALLR (SEQ ID NO: 68), ASPQQSGQGQQPGQE (SEQ ID NO: 69), GQGQQPGQEQQPGQG (SEQ ID NO: 70), QQPGQGQQDQQPGQR (SEQ ID NO: 71), QPGQKQQAGQGQQSG (SEQ ID NO: 72), QSGQGQQPGQGQPGY (SEQ ID NO: 73), QPGQGQQPGQGQQSG (SEQ ID NO: 74), SLRQPGQWQQPGQGQ (SEQ ID NO: 75), PQQSGQGQQLGQGQP (SEQ ID NO: 76), GQQPAQGQQSAQEQQ (SEQ ID NO: 77), PQQSGQGQQPGHEQQ (SEQ ID NO: 78), and EQQPGQWLQPGQGQQ (SEQ ID NO: 79).

46. The method of claim 45, wherein the wheat peptide derived from hmw comprisesan amino acid sequence QPGQGQQPGQGQQSG (SEQ ID NO: 74).

47. The method of claim 34, wherein the one or more wheat peptides comprise anamino acid sequence selected from the group consisting of LSQQQQPPFSQQQPP (SEQ ID NO: 8), GQQQPFPPQQPYPQP (SEQ ID NO: 17), QPFPPQQSYPQPQPQ (SEQ ID NO: 20), LTILAMAITIGTANM (SEQ ID NO: 27), PFSQQPQQTFPQPQQ (SEQ ID NO: 30), FPQPQQTFPHQPQQQ (SEQ ID NO: 31), TFPHQPQQQFPQPQQ (SEQ ID NO: 32), QQQFPQPQQPQQQFL (SEQ ID NO: 33), QPQQPFPQQPQQPYP (SEQ ID NO: 34),27527-0242WO1; ISMMS Ref.231101 PQQPYPQQPQQPFPQ (SEQ ID NO: 35), PQQSFPQQQPPFIQP (SEQ ID NO: 40), PQQPFPQPQQTFPQQ (SEQ ID NO: 43), PFPQQPQQPFPQPQQ (SEQ ID NO: 44), PQQFPQQQQFPQQHQ (SEQ ID NO: 49), FPQQQEFPQQQFPQQ (SEQ ID NO: 52), PEQQQFPQQQFPQQP (SEQ ID NO: 54), QQSFSYQQQPFPQQP (SEQ ID NO: 55), QQQPFPQQPYPQQPY (SEQ ID NO: 56), QPQQPFPQQPQQPQQ (SEQ ID NO: 57), PFPQPQQPFPWQPQQ (SEQ ID NO: 59), STHHFPAQQPFPQQP (SEQ ID NO: 62), and QPGQGQQPGQGQQSG (SEQ ID NO: 74).

48. The method of claim 34, wherein the one or more wheat peptides comprise anamino acid sequence selected from the group consisting of LSQQQQPPFSQQQPP (SEQ ID NO: 8), GQQQPFPPQQPYPQP (SEQ ID NO: 17), QPFPPQQSYPQPQPQ (SEQ ID NO: 20), QQQFPQPQQPQQQFL (SEQ ID NO: 33), QPQQPFPQQPQQPYP (SEQ ID NO: 34), PQQPFPQPQQTFPQQ (SEQ ID NO: 43), PFPQQPQQPFPQPQQ (SEQ ID NO: 44), PQQFPQQQQFPQQHQ (SEQ ID NO: 49), FPQQQEFPQQQFPQQ (SEQ ID NO: 52), PEQQQFPQQQFPQQP (SEQ ID NO: 54), QQSFSYQQQPFPQQP (SEQ ID NO: 55), QQQPFPQQPYPQQPY (SEQ ID NO: 56), QPQQPFPQQPQQPQQ (SEQ ID NO: 57), and QPGQGQQPGQGQQSG (SEQ ID NO: 74).

49. The method of any one of claims 30 to 33, wherein the one or more wheatpeptides is derived from gamma gliadin (gam) and / or omega-5-gliadin (omg).

50. The method of claim 49, wherein the one or more wheat peptides comprise anamino acid sequence selected from the group consisting of QQQFPQPQQPQQQFL (SEQ ID NO: 33), QPQQPFPQQPQQPYP (SEQ ID NO: 34), PQQPFPQPQQTFPQQ (SEQ ID NO: 43), PFPQQPQQPFPQPQQ (SEQ ID NO: 44), PQQFPQQQQFPQQHQ (SEQ ID NO: 49), FPQQQEFPQQQFPQQ (SEQ ID NO: 52), PEQQQFPQQQFPQQP (SEQ ID NO: 54), QQSFSYQQQPFPQQP (SEQ ID NO: 55), QQQPFPQQPYPQQPY (SEQ ID NO: 56), and QPQQPFPQQPQQPQQ (SEQ ID NO: 57).27527-0242WO1; ISMMS Ref.23110151. The method of any one of claims 30 to 50, wherein each of the wheat peptidescomprises a linker for coupling to the solid support.

52. The method of claim 51, wherein the linker is -PEG12-biotin.

53. The method of any one of claims 30 to 52, wherein the solid support is amicrosphere bead, glass array, silicone array, membrane, or microtiter plate.

54. The method of any one of claims 30 to 53, wherein the AAI is IgG and / or IgE.

55. The method of claim 54, wherein the IgG is IgG4.

56. The method of any one of claims 30 to 55, wherein the AAI-specific labelingreagent is a detectably labeled anti-human IgG antibody and / or a detectably labeled anti- human IgE antibody.

57. The method of claim 56, wherein the detectable label is phycoerythrin, afluorescent dye, horse radish peroxidase (HRP), or alkaline phosphatase.

58. The method of any one of claims 30 to 57, wherein the detection of the binding ofthe AAI-specific labeling reagent to each AAI-peptide-solid support complex is carried out by a multiplex peptide-bead assay for flow cytometric analysis or a lateral flow assay.

59. A method for detecting an increase in intensity of allergy or adverse event duringtreatment of allergy to wheat over time in a subject that is allergic to wheat comprising: contacting one or more wheat peptides with serum or plasma obtained from the subject under conditions sufficient to permit binding of one or more allergy associated immunoglobulins (AAIs) in the serum or plasma to the one or more wheat peptides, wherein the one or more wheat peptides are coupled to a solid support, to form one or more AAI-peptide-solid support complexes;27527-0242WO1; ISMMS Ref.231101 binding an AAI-specific labeling reagent to the AAI-peptide-solid support complex; detecting binding of the AAI-specific labeling reagent to each AAI-peptide-solid support complex to identify one or more wheat peptides bound to the AAI in the serum or plasma of the subject; and comparing the identified one or more wheat peptides bound to the AAI in the serum or plasma of the subject, or the concentration of the AAI in the serum or plasma of the subject, with a previously identified panel of one or more wheat peptides bound to the AAI in the serum of the subject, or a previous concentration of the AAI in the serum or plasma of the subject; wherein an increased intensity of the allergic response to wheat is indicated when the subsequent number or pattern of reactivity of wheat peptides recognized by AAI in the serum or plasma of the subject, or the subsequent concentration of AAI in the serum or plasma of the subject, is greater than the previously identified number or pattern of reactivity of wheat peptides recognized by AAI in the serum or plasma of the subject, or greater than the previous concentration of AAI in the serum or plasma of the subject.

60. The method of claim 59, wherein each wheat peptide comprises from about fromabout 6 amino acids to about 30 amino acids, from about 7 amino acids to about 20 amino acids, from about 10 amino acids to about 18 amino acids, or from about 12 amino acids to about 16 amino acids.

61. The method of claim 59, wherein each wheat peptide comprises 15 amino acids.

62. The method of any one of claims 59 to 61, wherein the one or more wheatpeptides comprise at least 2 wheat peptides, at least 3 wheat peptides, at least 5 wheat peptides, at least 10 wheat peptides, at least 15 wheat peptides, at least 20 wheat peptides, or at least 25 what peptides.27527-0242WO1; ISMMS Ref.23110163. The method of any one of claims 59 to 62, wherein the one or more wheatpeptides is derived from low molecular weight glutenin (lmw), alpha / beta gliadin (alb), gamma gliadin (gam), omega-5-gliadin (omg), and / or high molecular weight glutenin (hmw).

64. The method of claim 63, wherein the one or more wheat peptides derived fromlmw comprise an amino acid sequence selected from the group consisting of ENSHIPGLERPSQQQ (SEQ ID NO: 1), HIPGLERPSQQQPLP (SEQ ID NO: 2), RPSQQQPLPPQQTLS (SEQ ID NO: 3), QQQPIQQQPQPFSQQ (SEQ ID NO: 4), PIQQQPQPFSQQQPC (SEQ ID NO: 5), QQQPLSQQQQPPFSQ (SEQ ID NO: 6), QQQQPPFSQQQPPFS (SEQ ID NO: 7), LSQQQQPPFSQQQPP (SEQ ID NO: 8), FSQQQQPPFSQQQPP (SEQ ID NO: 9), FSQQQQPVLPQQPSF (SEQ ID NO: 10), GSIQTPQQQPQQLGQ (SEQ ID NO: 11), QPQQQSQQQLGQQPQ (SEQ ID NO: 12), and QQQLGQQPQQQQLAQ (SEQ ID NO: 13).

65. The method of claim 64, wherein the wheat peptide derived from lmw comprisesan amino acid sequence LSQQQQPPFSQQQPP (SEQ ID NO: 8).

66. The method of claim 63, wherein the one or more wheat peptides derived from albcomprise an amino acid sequence selected from the group consisting of PVPQLQPQNPSQQQP (SEQ ID NO: 14), PQNPSQQQPQEQVPL (SEQ ID NO: 15), LGQQQQHFPGQQQPF (SEQ ID NO: 16), GQQQPFPPQQPYPQP (SEQ ID NO: 17), QPFPPQQPYPQPQPF (SEQ ID NO: 18), LPYPQPQPFPPQQSY (SEQ ID NO: 19), QPFPPQQSYPQPQPQ (SEQ ID NO: 20), QPQYPQPQQPISQQQ (SEQ ID NO: 21), SSQVSQQSYQLLQQL (SEQ ID NO: 22), QQPSSQVSYQQPQQQ (SEQ ID NO: 23), VSYQQPQQQYPSGQG (SEQ ID NO: 24), QQQYPSGQGSFQPSQ (SEQ ID NO: 25), and QLPQFEEIRNLALQT (SEQ ID NO: 26).

67. The method of claim 66, wherein the one or more wheat peptides derived from albcomprise an amino acid sequence GQQQPFPPQQPYPQP (SEQ ID NO: 17) or QPFPPQQSYPQPQPQ (SEQ ID NO: 20).27527-0242WO1; ISMMS Ref.23110168. The method of claim 63, wherein the one or more wheat peptides derived fromgam comprise an amino acid sequence selected from the group consisting of LTILAMAITIGTANM (SEQ ID NO: 27), WPQQQPVPQPHQPFS (SEQ ID NO: 28), VPQPHQPFSQQPQQT (SEQ ID NO: 29), PFSQQPQQTFPQPQQ (SEQ ID NO: 30), FPQPQQTFPHQPQQQ (SEQ ID NO: 31), TFPHQPQQQFPQPQQ (SEQ ID NO: 32), QQQFPQPQQPQQQFL (SEQ ID NO: 33), QPQQPFPQQPQQPYP (SEQ ID NO: 34), PQQPYPQQPQQPFPQ (SEQ ID NO: 35), QQPFPQTQQPQQLFP (SEQ ID NO: 36), LFPQSQQPQQQFSQP (SEQ ID NO: 37), QPQQQFSQPQQQFPQ (SEQ ID NO: 38), FPQPQQPQQSFPQQQ (SEQ ID NO: 39), PQQSFPQQQPPFIQP (SEQ ID NO: 40), IMQQEQQEQQQGMHI (SEQ ID NO: 41), VQGQGIIQPQQPAQL (SEQ ID NO: 42), PQQPFPQPQQTFPQQ (SEQ ID NO: 43), PFPQQPQQPFPQPQQ (SEQ ID NO: 44), and IQSFLQQQMNPCKNF (SEQ ID NO: 45).

69. The method of claim 68, wherein the one or more wheat peptides derived fromgam comprise an amino acid sequence selected from the group consisting of LTILAMAITIGTANM (SEQ ID NO: 27), PFSQQPQQTFPQPQQ (SEQ ID NO: 30), FPQPQQTFPHQPQQQ (SEQ ID NO: 31), TFPHQPQQQFPQPQQ (SEQ ID NO: 32), QQQFPQPQQPQQQFL (SEQ ID NO: 33), QPQQPFPQQPQQPYP (SEQ ID NO: 34), PQQPYPQQPQQPFPQ (SEQ ID NO: 35), PQQSFPQQQPPFIQP (SEQ ID NO: 40), PQQPFPQPQQTFPQQ (SEQ ID NO: 43), and PFPQQPQQPFPQPQQ (SEQ ID NO: 44).

70. The method of claim 68, wherein the one or more wheat peptides derived fromgam comprise an amino acid sequence selected from the group consisting of QQQFPQPQQPQQQFL (SEQ ID NO: 33), QPQQPFPQQPQQPYP (SEQ ID NO: 34), PQQPFPQPQQTFPQQ (SEQ ID NO: 43), and PFPQQPQQPFPQPQQ (SEQ ID NO: 44).

71. The method of claim 63, wherein the one or more wheat peptides derived fromomg comprise an amino acid sequence selected from the group consisting of AMNIASASRLLSPRG (SEQ ID NO: 46), PRGKELHTPQEQFPQ (SEQ ID NO: 47), HTPQEQFPQQQQFPQ (SEQ ID NO: 48), PQQFPQQQQFPQQHQ (SEQ ID NO: 49),27527-0242WO1; ISMMS Ref.231101 QQIPQQPQQFLQQQQ (SEQ ID NO: 50),FPQQQSPQQQQFPQQ (SEQ ID NO: 51), FPQQQEFPQQQFPQQ (SEQ ID NO: 52), QQFPRPQQSPEQQQF (SEQ ID NO: 53), PEQQQFPQQQFPQQP (SEQ ID NO: 54), QQSFSYQQQPFPQQP (SEQ ID NO: 55), QQQPFPQQPYPQQPY (SEQ ID NO: 56), QPQQPFPQQPQQPQQ (SEQ ID NO: 57), QPFPQQPQQPQQPFP (SEQ ID NO: 58), PFPQPQQPFPWQPQQ (SEQ ID NO: 59), QFQESIKHKSKMKTF (SEQ ID NO: 60), QQRFPHTRQKFPRNP (SEQ ID NO: 61), STHHFPAQQPFPQQP (SEQ ID NO: 62), and PFPQQPGQIIPQQPQ (SEQ ID NO: 63).

72. The method of claim 71, wherein the one or more wheat peptides derived fromomg comprise an amino acid sequence selected from the group consisting of PQQFPQQQQFPQQHQ (SEQ ID NO: 49), FPQQQEFPQQQFPQQ (SEQ ID NO: 52), PEQQQFPQQQFPQQP (SEQ ID NO: 54), QQSFSYQQQPFPQQP (SEQ ID NO: 55), QQQPFPQQPYPQQPY (SEQ ID NO: 56), QPQQPFPQQPQQPQQ (SEQ ID NO: 57), PFPQPQQPFPWQPQQ (SEQ ID NO: 59), and STHHFPAQQPFPQQP (SEQ ID NO: 62).

73. The method of claim 71, wherein the one or more wheat peptides derived fromomg comprise an amino acid sequence selected from the group consisting of PQQFPQQQQFPQQHQ (SEQ ID NO: 49), FPQQQEFPQQQFPQQ (SEQ ID NO: 52), PEQQQFPQQQFPQQP (SEQ ID NO: 54), QQSFSYQQQPFPQQP (SEQ ID NO: 55), QQQPFPQQPYPQQPY (SEQ ID NO: 56), and QPQQPFPQQPQQPQQ (SEQ ID NO: 57).

74. The method of claim 63, wherein the one or more wheat peptides derived fromhmw comprise an amino acid sequence selected from the group consisting of SPQRPGQGQQPGQGQ (SEQ ID NO: 64), QGQQPGQGQQGQQPG (SEQ ID NO: 65), QQPGQGQQPGQLQQP (SEQ ID NO: 66), QQPAQGQQGQQPGQG (SEQ ID NO: 67), QLQQMIFWGIPALLR (SEQ ID NO: 68), ASPQQSGQGQQPGQE (SEQ ID NO: 69), GQGQQPGQEQQPGQG (SEQ ID NO: 70), QQPGQGQQDQQPGQR (SEQ ID NO: 71), QPGQKQQAGQGQQSG (SEQ ID NO: 72), QSGQGQQPGQGQPGY (SEQ ID NO: 73), QPGQGQQPGQGQQSG (SEQ ID NO: 74), SLRQPGQWQQPGQGQ (SEQ ID NO: 75), PQQSGQGQQLGQGQP (SEQ ID NO: 76), GQQPAQGQQSAQEQQ (SEQ ID NO: 77),27527-0242WO1; ISMMS Ref.231101 PQQSGQGQQPGHEQQ (SEQ ID NO: 78), and EQQPGQWLQPGQGQQ (SEQ ID NO: 79).

75. The method of claim 74, wherein the wheat peptide derived from hmw comprisesan amino acid sequence QPGQGQQPGQGQQSG (SEQ ID NO: 74).

76. The method of claim 63, wherein the one or more wheat peptides comprise anamino acid sequence selected from the group consisting of LSQQQQPPFSQQQPP (SEQ ID NO: 8), GQQQPFPPQQPYPQP (SEQ ID NO: 17), QPFPPQQSYPQPQPQ (SEQ ID NO: 20), LTILAMAITIGTANM (SEQ ID NO: 27), PFSQQPQQTFPQPQQ (SEQ ID NO: 30), FPQPQQTFPHQPQQQ (SEQ ID NO: 31), TFPHQPQQQFPQPQQ (SEQ ID NO: 32), QQQFPQPQQPQQQFL (SEQ ID NO: 33), QPQQPFPQQPQQPYP (SEQ ID NO: 34), PQQPYPQQPQQPFPQ (SEQ ID NO: 35), PQQSFPQQQPPFIQP (SEQ ID NO: 40), PQQPFPQPQQTFPQQ (SEQ ID NO: 43), PFPQQPQQPFPQPQQ (SEQ ID NO: 44), PQQFPQQQQFPQQHQ (SEQ ID NO: 49), FPQQQEFPQQQFPQQ (SEQ ID NO: 52), PEQQQFPQQQFPQQP (SEQ ID NO: 54), QQSFSYQQQPFPQQP (SEQ ID NO: 55), QQQPFPQQPYPQQPY (SEQ ID NO: 56), QPQQPFPQQPQQPQQ (SEQ ID NO: 57), PFPQPQQPFPWQPQQ (SEQ ID NO: 59), STHHFPAQQPFPQQP (SEQ ID NO: 62), and QPGQGQQPGQGQQSG (SEQ ID NO: 74).

77. The method of claim 63, wherein the one or more wheat peptides comprise anamino acid sequence selected from the group consisting of LSQQQQPPFSQQQPP (SEQ ID NO: 8), GQQQPFPPQQPYPQP (SEQ ID NO: 17), QPFPPQQSYPQPQPQ (SEQ ID NO: 20), QQQFPQPQQPQQQFL (SEQ ID NO: 33), QPQQPFPQQPQQPYP (SEQ ID NO: 34), PQQPFPQPQQTFPQQ (SEQ ID NO: 43), PFPQQPQQPFPQPQQ (SEQ ID NO: 44), PQQFPQQQQFPQQHQ (SEQ ID NO: 49), FPQQQEFPQQQFPQQ (SEQ ID NO: 52), PEQQQFPQQQFPQQP (SEQ ID NO: 54), QQSFSYQQQPFPQQP (SEQ ID NO: 55), QQQPFPQQPYPQQPY (SEQ ID NO: 56), QPQQPFPQQPQQPQQ (SEQ ID NO: 57), and QPGQGQQPGQGQQSG (SEQ ID NO: 74).27527-0242WO1; ISMMS Ref.23110178. The method of any one of claims 59 to 62, wherein the one or more wheatpeptides is derived from gamma gliadin (gam) and / or omega-5-gliadin (omg).

79. The method of claim 78, wherein the one or more wheat peptides comprise anamino acid sequence selected from the group consisting of QQQFPQPQQPQQQFL (SEQ ID NO: 33), QPQQPFPQQPQQPYP (SEQ ID NO: 34), PQQPFPQPQQTFPQQ (SEQ ID NO: 43), PFPQQPQQPFPQPQQ (SEQ ID NO: 44), PQQFPQQQQFPQQHQ (SEQ ID NO: 49), FPQQQEFPQQQFPQQ (SEQ ID NO: 52), PEQQQFPQQQFPQQP (SEQ ID NO: 54), QQSFSYQQQPFPQQP (SEQ ID NO: 55), QQQPFPQQPYPQQPY (SEQ ID NO: 56), and QPQQPFPQQPQQPQQ (SEQ ID NO: 57).

80. The method of any one of claims 59 to 79, wherein each of the wheat peptidescomprises a linker for coupling to the solid support.

81. The method of claim 80, wherein the linker is -PEG12-biotin.

82. The method of any one of claims 59 to 81, wherein the solid support is amicrosphere bead, glass array, silicone array, membrane, or microtiter plate.

83. The method of any one of claims 59 to 82, wherein the AAI is IgG and / or IgE.

84. The method of claim 83, wherein the IgG is IgG4.

85. The method of any one of claims 59 to 84, wherein the AAI-specific labelingreagent is a detectably labeled anti-human IgG antibody and / or a detectably labeled anti- human IgE antibody.

86. The method of claim 84, wherein the detectable label is phycoerythrin, afluorescent dye, horse radish peroxidase (HRP), or alkaline phosphatase.27527-0242WO1; ISMMS Ref.23110187. The method of any one of claims 59 to 86, wherein the detection of the binding ofthe AAI-specific labeling reagent to each AAI-peptide-solid support complex is carried out by a multiplex peptide-bead assay for flow cytometric analysis or a lateral flow assay.

88. A method of sensitizing an infant to one or more wheat allergens to inducetolerance or non-allergy to wheat comprising administering one or more wheat peptides to the infant, wherein the one or more wheat peptides are derived from low molecular weight glutenin (lmw), alpha / beta gliadin (alb), gamma gliadin (gam), omega-5-gliadin (omg), and / or high molecular weight glutenin (hmw).

89. The method of claim 88, wherein each wheat peptide comprises from about fromabout 6 amino acids to about 30 amino acids, from about 7 amino acids to about 20 amino acids, from about 10 amino acids to about 18 amino acids, or from about 12 amino acids to about 16 amino acids.

90. The method of claim 88, wherein each wheat peptide comprises 15 amino acids.

91. The method of any one of claims 88 to 90, wherein the one or more wheatpeptides comprise at least 2 wheat peptides, at least 3 wheat peptides, at least 5 wheat peptides, at least 10 wheat peptides, at least 15 wheat peptides, at least 20 wheat peptides, or at least 25 what peptides.

92. The method of claim 88, wherein the wheat peptide derived from lmw comprisesan amino acid sequence LSQQQQPPFSQQQPP (SEQ ID NO: 8).

93. The method of claim 88, wherein the one or more wheat peptides derived from albcomprise an amino acid sequence GQQQPFPPQQPYPQP (SEQ ID NO: 17) or QPFPPQQSYPQPQPQ (SEQ ID NO: 20).27527-0242WO1; ISMMS Ref.23110194. The method of claim 88, wherein the one or more wheat peptides derived fromgam comprise an amino acid sequence selected from the group consisting of LTILAMAITIGTANM (SEQ ID NO: 27), PFSQQPQQTFPQPQQ (SEQ ID NO: 30), FPQPQQTFPHQPQQQ (SEQ ID NO: 31), TFPHQPQQQFPQPQQ (SEQ ID NO: 32), QQQFPQPQQPQQQFL (SEQ ID NO: 33), QPQQPFPQQPQQPYP (SEQ ID NO: 34), PQQPYPQQPQQPFPQ (SEQ ID NO: 35), PQQSFPQQQPPFIQP (SEQ ID NO: 40), PQQPFPQPQQTFPQQ (SEQ ID NO: 43), and PFPQQPQQPFPQPQQ (SEQ ID NO: 44).

95. The method of claim 94, wherein the one or more wheat peptides derived fromgam comprise an amino acid sequence selected from the group consisting of QQQFPQPQQPQQQFL (SEQ ID NO: 33), QPQQPFPQQPQQPYP (SEQ ID NO: 34), PQQPFPQPQQTFPQQ (SEQ ID NO: 43), and PFPQQPQQPFPQPQQ (SEQ ID NO: 44).

96. The method of claim 88, wherein the one or more wheat peptides derived fromomg comprise an amino acid sequence selected from the group consisting of PQQFPQQQQFPQQHQ (SEQ ID NO: 49), FPQQQEFPQQQFPQQ (SEQ ID NO: 52), PEQQQFPQQQFPQQP (SEQ ID NO: 54), QQSFSYQQQPFPQQP (SEQ ID NO: 55), QQQPFPQQPYPQQPY (SEQ ID NO: 56), QPQQPFPQQPQQPQQ (SEQ ID NO: 57), PFPQPQQPFPWQPQQ (SEQ ID NO: 59), and STHHFPAQQPFPQQP (SEQ ID NO: 62).

97. The method of claim 96, wherein the one or more wheat peptides derived fromomg comprise an amino acid sequence selected from the group consisting of PQQFPQQQQFPQQHQ (SEQ ID NO: 49), FPQQQEFPQQQFPQQ (SEQ ID NO: 52), PEQQQFPQQQFPQQP (SEQ ID NO: 54), QQSFSYQQQPFPQQP (SEQ ID NO: 55), QQQPFPQQPYPQQPY (SEQ ID NO: 56), and QPQQPFPQQPQQPQQ (SEQ ID NO: 57).

98. The method of claim 88, wherein the wheat peptide derived from hmw comprisesan amino acid sequence QPGQGQQPGQGQQSG (SEQ ID NO: 74).27527-0242WO1; ISMMS Ref.23110199. The method of claim 88, wherein the one or more wheat peptides comprise anamino acid sequence selected from the group consisting of LSQQQQPPFSQQQPP (SEQ ID NO: 8), GQQQPFPPQQPYPQP (SEQ ID NO: 17), QPFPPQQSYPQPQPQ (SEQ ID NO: 20), LTILAMAITIGTANM (SEQ ID NO: 27), PFSQQPQQTFPQPQQ (SEQ ID NO: 30), FPQPQQTFPHQPQQQ (SEQ ID NO: 31), TFPHQPQQQFPQPQQ (SEQ ID NO: 32), QQQFPQPQQPQQQFL (SEQ ID NO: 33), QPQQPFPQQPQQPYP (SEQ ID NO: 34), PQQPYPQQPQQPFPQ (SEQ ID NO: 35), PQQSFPQQQPPFIQP (SEQ ID NO: 40), PQQPFPQPQQTFPQQ (SEQ ID NO: 43), PFPQQPQQPFPQPQQ (SEQ ID NO: 44), PQQFPQQQQFPQQHQ (SEQ ID NO: 49), FPQQQEFPQQQFPQQ (SEQ ID NO: 52), PEQQQFPQQQFPQQP (SEQ ID NO: 54), QQSFSYQQQPFPQQP (SEQ ID NO: 55), QQQPFPQQPYPQQPY (SEQ ID NO: 56), QPQQPFPQQPQQPQQ (SEQ ID NO: 57), PFPQPQQPFPWQPQQ (SEQ ID NO: 59), STHHFPAQQPFPQQP (SEQ ID NO: 62), and QPGQGQQPGQGQQSG (SEQ ID NO: 74).

100. The method of claim 88, wherein the one or more wheat peptides comprise an amino acid sequence selected from the group consisting of LSQQQQPPFSQQQPP (SEQ ID NO: 8), GQQQPFPPQQPYPQP (SEQ ID NO: 17), QPFPPQQSYPQPQPQ (SEQ ID NO: 20), QQQFPQPQQPQQQFL (SEQ ID NO: 33), QPQQPFPQQPQQPYP (SEQ ID NO: 34), PQQPFPQPQQTFPQQ (SEQ ID NO: 43), PFPQQPQQPFPQPQQ (SEQ ID NO: 44), PQQFPQQQQFPQQHQ (SEQ ID NO: 49), FPQQQEFPQQQFPQQ (SEQ ID NO: 52), PEQQQFPQQQFPQQP (SEQ ID NO: 54), QQSFSYQQQPFPQQP (SEQ ID NO: 55), QQQPFPQQPYPQQPY (SEQ ID NO: 56), QPQQPFPQQPQQPQQ (SEQ ID NO: 57), and QPGQGQQPGQGQQSG (SEQ ID NO: 74).

101. The method of any one of claims 88 to 91, wherein the one or more wheat peptides is derived from gamma gliadin (gam) and / or omega-5-gliadin (omg).

102. The method of claim 101, wherein the one or more wheat peptides comprise an amino acid sequence selected from the group consisting of QQQFPQPQQPQQQFL (SEQ ID NO: 33), QPQQPFPQQPQQPYP (SEQ ID NO: 34), PQQPFPQPQQTFPQQ (SEQ ID NO: 43),27527-0242WO1; ISMMS Ref.231101 PFPQQPQQPFPQPQQ (SEQ ID NO: 44), PQQFPQQQQFPQQHQ (SEQ ID NO: 49), FPQQQEFPQQQFPQQ (SEQ ID NO: 52), PEQQQFPQQQFPQQP (SEQ ID NO: 54), QQSFSYQQQPFPQQP (SEQ ID NO: 55), QQQPFPQQPYPQQPY (SEQ ID NO: 56), and QPQQPFPQQPQQPQQ (SEQ ID NO: 57).

103. A set of allergenic epitope-containing wheat peptides comprising a plurality of wheat peptides comprising at least two peptides derived from low molecular weight glutenin (lmw), alpha / beta gliadin (alb), gamma gliadin (gam), omega-5-gliadin (omg), and / or high molecular weight glutenin (hmw).

104. The set of peptides of claim 103, wherein each wheat peptide comprises from about from about 6 amino acids to about 30 amino acids, from about 7 amino acids to about 20 amino acids, from about 10 amino acids to about 18 amino acids, or from about 12 amino acids to about 16 amino acids.

105. The set of peptides of claim 103, wherein each wheat peptide comprises 15 amino acids.

106. The set of peptides of any one of claims 103 to 105, wherein the one or more wheat peptides comprise at least 2 wheat peptides, at least 3 wheat peptides, at least 5 wheat peptides, at least 10 wheat peptides, at least 15 wheat peptides, at least 20 wheat peptides, or at least 25 what peptides.

107. The set of peptides of claim 103, wherein the wheat peptide derived from lmw comprises an amino acid sequence LSQQQQPPFSQQQPP (SEQ ID NO: 8).

108. The set of peptides of claim 103, wherein the one or more wheat peptides derived from alb comprise an amino acid sequence GQQQPFPPQQPYPQP (SEQ ID NO: 17) or QPFPPQQSYPQPQPQ (SEQ ID NO: 20).27527-0242WO1; ISMMS Ref.231101 109. The set of peptides of claim 103, wherein the one or more wheat peptides derived from gam comprise an amino acid sequence selected from the group consisting of LTILAMAITIGTANM (SEQ ID NO: 27), PFSQQPQQTFPQPQQ (SEQ ID NO: 30), FPQPQQTFPHQPQQQ (SEQ ID NO: 31), TFPHQPQQQFPQPQQ (SEQ ID NO: 32), QQQFPQPQQPQQQFL (SEQ ID NO: 33), QPQQPFPQQPQQPYP (SEQ ID NO: 34), PQQPYPQQPQQPFPQ (SEQ ID NO: 35), PQQSFPQQQPPFIQP (SEQ ID NO: 40), PQQPFPQPQQTFPQQ (SEQ ID NO: 43), and PFPQQPQQPFPQPQQ (SEQ ID NO: 44).

110. The set of peptides of claim 109, wherein the one or more wheat peptides derived from gam comprise an amino acid sequence selected from the group consisting of QQQFPQPQQPQQQFL (SEQ ID NO: 33), QPQQPFPQQPQQPYP (SEQ ID NO: 34), PQQPFPQPQQTFPQQ (SEQ ID NO: 43), and PFPQQPQQPFPQPQQ (SEQ ID NO: 44).

111. The set of peptides of claim 103, wherein the one or more wheat peptides derived from omg comprise an amino acid sequence selected from the group consisting of PQQFPQQQQFPQQHQ (SEQ ID NO: 49), FPQQQEFPQQQFPQQ (SEQ ID NO: 52), PEQQQFPQQQFPQQP (SEQ ID NO: 54), QQSFSYQQQPFPQQP (SEQ ID NO: 55), QQQPFPQQPYPQQPY (SEQ ID NO: 56), QPQQPFPQQPQQPQQ (SEQ ID NO: 57), PFPQPQQPFPWQPQQ (SEQ ID NO: 59), and STHHFPAQQPFPQQP (SEQ ID NO: 62).

112. The set of peptides of claim 111, wherein the one or more wheat peptides derived from omg comprise an amino acid sequence selected from the group consisting of PQQFPQQQQFPQQHQ (SEQ ID NO: 49), FPQQQEFPQQQFPQQ (SEQ ID NO: 52), PEQQQFPQQQFPQQP (SEQ ID NO: 54), QQSFSYQQQPFPQQP (SEQ ID NO: 55), QQQPFPQQPYPQQPY (SEQ ID NO: 56), and QPQQPFPQQPQQPQQ (SEQ ID NO: 57).

113. The set of peptides of claim 103, wherein the wheat peptide derived from hmw comprises an amino acid sequence QPGQGQQPGQGQQSG (SEQ ID NO: 74).27527-0242WO1; ISMMS Ref.231101 114. The set of peptides of claim 103, wherein the one or more wheat peptides comprise an amino acid sequence selected from the group consisting of LSQQQQPPFSQQQPP (SEQ ID NO: 8), GQQQPFPPQQPYPQP (SEQ ID NO: 17), QPFPPQQSYPQPQPQ (SEQ ID NO: 20), LTILAMAITIGTANM (SEQ ID NO: 27), PFSQQPQQTFPQPQQ (SEQ ID NO: 30), FPQPQQTFPHQPQQQ (SEQ ID NO: 31), TFPHQPQQQFPQPQQ (SEQ ID NO: 32), QQQFPQPQQPQQQFL (SEQ ID NO: 33), QPQQPFPQQPQQPYP (SEQ ID NO: 34), PQQPYPQQPQQPFPQ (SEQ ID NO: 35), PQQSFPQQQPPFIQP (SEQ ID NO: 40), PQQPFPQPQQTFPQQ (SEQ ID NO: 43), PFPQQPQQPFPQPQQ (SEQ ID NO: 44), PQQFPQQQQFPQQHQ (SEQ ID NO: 49), FPQQQEFPQQQFPQQ (SEQ ID NO: 52), PEQQQFPQQQFPQQP (SEQ ID NO: 54), QQSFSYQQQPFPQQP (SEQ ID NO: 55), QQQPFPQQPYPQQPY (SEQ ID NO: 56), QPQQPFPQQPQQPQQ (SEQ ID NO: 57), PFPQPQQPFPWQPQQ (SEQ ID NO: 59), STHHFPAQQPFPQQP (SEQ ID NO: 62), and QPGQGQQPGQGQQSG (SEQ ID NO: 74).

115. The set of peptides of claim 103, wherein the one or more wheat peptides comprise an amino acid sequence selected from the group consisting of LSQQQQPPFSQQQPP (SEQ ID NO: 8), GQQQPFPPQQPYPQP (SEQ ID NO: 17), QPFPPQQSYPQPQPQ (SEQ ID NO: 20), QQQFPQPQQPQQQFL (SEQ ID NO: 33), QPQQPFPQQPQQPYP (SEQ ID NO: 34), PQQPFPQPQQTFPQQ (SEQ ID NO: 43), PFPQQPQQPFPQPQQ (SEQ ID NO: 44), PQQFPQQQQFPQQHQ (SEQ ID NO: 49), FPQQQEFPQQQFPQQ (SEQ ID NO: 52), PEQQQFPQQQFPQQP (SEQ ID NO: 54), QQSFSYQQQPFPQQP (SEQ ID NO: 55), QQQPFPQQPYPQQPY (SEQ ID NO: 56), QPQQPFPQQPQQPQQ (SEQ ID NO: 57), and QPGQGQQPGQGQQSG (SEQ ID NO: 74).

116. The set of peptides of any one of claims 103 to 106, wherein the one or more wheat peptides is derived from gamma gliadin (gam) and / or omega-5-gliadin (omg).

117. The set of peptides of claim 116, wherein the one or more wheat peptides comprise an amino acid sequence selected from the group consisting of QQQFPQPQQPQQQFL (SEQ ID NO: 33), QPQQPFPQQPQQPYP (SEQ ID NO: 34),27527-0242WO1; ISMMS Ref.231101 PQQPFPQPQQTFPQQ (SEQ ID NO: 43), PFPQQPQQPFPQPQQ (SEQ ID NO: 44), PQQFPQQQQFPQQHQ (SEQ ID NO: 49), FPQQQEFPQQQFPQQ (SEQ ID NO: 52), PEQQQFPQQQFPQQP (SEQ ID NO: 54), QQSFSYQQQPFPQQP (SEQ ID NO: 55), QQQPFPQQPYPQQPY (SEQ ID NO: 56), and QPQQPFPQQPQQPQQ (SEQ ID NO: 57).

118. A kit comprising: a) one or more allergenic epitope-containing wheat peptides derived from low molecular weight glutenin (lmw), alpha / beta gliadin (alb), gamma gliadin (gam), omega-5- gliadin (omg), and / or high molecular weight glutenin (hmw), wherein each wheat peptide is coupled to a solid support; and b) an allergy associated immunoglobulin (AAI)-specific labeling reagent; packaged together and including instructions for use.

119. The kit of claim 118, further comprising one or more of a binding buffer, a wash buffer, and a detection buffer.

120. The kit of claim 118 or claim 119, further comprising a reporter moiety that specifically binds to the AAI-specific labeling reagent.

121. The kit of any one of claims 118 to 120, wherein each wheat peptide comprises from about from about 6 amino acids to about 30 amino acids, from about 7 amino acids to about 20 amino acids, from about 10 amino acids to about 18 amino acids, or from about 12 amino acids to about 16 amino acids.

122. The kit of claim 118, wherein each wheat peptide comprises 15 amino acids.

123. The kit of any one of claims 118 to 122, wherein the one or more wheat peptides comprise at least 2 wheat peptides, at least 3 wheat peptides, at least 5 wheat peptides, at least 10 wheat peptides, at least 15 wheat peptides, at least 20 wheat peptides, or at least 25 what peptides.27527-0242WO1; ISMMS Ref.231101 124. The kit of claim 118, wherein the one or more wheat peptides derived from lmw comprise an amino acid sequence selected from the group consisting of ENSHIPGLERPSQQQ (SEQ ID NO: 1), HIPGLERPSQQQPLP (SEQ ID NO: 2), RPSQQQPLPPQQTLS (SEQ ID NO: 3), QQQPIQQQPQPFSQQ (SEQ ID NO: 4), PIQQQPQPFSQQQPC (SEQ ID NO: 5), QQQPLSQQQQPPFSQ (SEQ ID NO: 6), QQQQPPFSQQQPPFS (SEQ ID NO: 7), LSQQQQPPFSQQQPP (SEQ ID NO: 8), FSQQQQPPFSQQQPP (SEQ ID NO: 9), FSQQQQPVLPQQPSF (SEQ ID NO: 10), GSIQTPQQQPQQLGQ (SEQ ID NO: 11), QPQQQSQQQLGQQPQ (SEQ ID NO: 12), and QQQLGQQPQQQQLAQ (SEQ ID NO: 13).

125. The kit of claim 124, wherein the wheat peptide derived from lmw comprises an amino acid sequence LSQQQQPPFSQQQPP (SEQ ID NO: 8).

126. The kit of claim 118, wherein the one or more wheat peptides derived from alb comprise an amino acid sequence selected from the group consisting of PVPQLQPQNPSQQQP (SEQ ID NO: 14), PQNPSQQQPQEQVPL (SEQ ID NO: 15), LGQQQQHFPGQQQPF (SEQ ID NO: 16), GQQQPFPPQQPYPQP (SEQ ID NO: 17), QPFPPQQPYPQPQPF (SEQ ID NO: 18), LPYPQPQPFPPQQSY (SEQ ID NO: 19), QPFPPQQSYPQPQPQ (SEQ ID NO: 20), QPQYPQPQQPISQQQ (SEQ ID NO: 21), SSQVSQQSYQLLQQL (SEQ ID NO: 22), QQPSSQVSYQQPQQQ (SEQ ID NO: 23), VSYQQPQQQYPSGQG (SEQ ID NO: 24), QQQYPSGQGSFQPSQ (SEQ ID NO: 25), and QLPQFEEIRNLALQT (SEQ ID NO: 26).

127. The kit of claim 126, wherein the one or more wheat peptides derived from alb comprise an amino acid sequence GQQQPFPPQQPYPQP (SEQ ID NO: 17) or QPFPPQQSYPQPQPQ (SEQ ID NO: 20).

128. The kit of claim 118, wherein the one or more wheat peptides derived from gam comprise an amino acid sequence selected from the group consisting of LTILAMAITIGTANM (SEQ ID NO: 27), WPQQQPVPQPHQPFS (SEQ ID NO: 28), VPQPHQPFSQQPQQT (SEQ ID NO: 29), PFSQQPQQTFPQPQQ (SEQ ID NO: 30),27527-0242WO1; ISMMS Ref.231101 FPQPQQTFPHQPQQQ (SEQ ID NO: 31), TFPHQPQQQFPQPQQ (SEQ ID NO: 32), QQQFPQPQQPQQQFL (SEQ ID NO: 33), QPQQPFPQQPQQPYP (SEQ ID NO: 34), PQQPYPQQPQQPFPQ (SEQ ID NO: 35), QQPFPQTQQPQQLFP (SEQ ID NO: 36), LFPQSQQPQQQFSQP (SEQ ID NO: 37), QPQQQFSQPQQQFPQ (SEQ ID NO: 38), FPQPQQPQQSFPQQQ (SEQ ID NO: 39), PQQSFPQQQPPFIQP (SEQ ID NO: 40), IMQQEQQEQQQGMHI (SEQ ID NO: 41), VQGQGIIQPQQPAQL (SEQ ID NO: 42), PQQPFPQPQQTFPQQ (SEQ ID NO: 43), PFPQQPQQPFPQPQQ (SEQ ID NO: 44), and IQSFLQQQMNPCKNF (SEQ ID NO: 45).

129. The kit of claim 128, wherein the one or more wheat peptides derived from gam comprise an amino acid sequence selected from the group consisting of LTILAMAITIGTANM (SEQ ID NO: 27), PFSQQPQQTFPQPQQ (SEQ ID NO: 30), FPQPQQTFPHQPQQQ (SEQ ID NO: 31), TFPHQPQQQFPQPQQ (SEQ ID NO: 32), QQQFPQPQQPQQQFL (SEQ ID NO: 33), QPQQPFPQQPQQPYP (SEQ ID NO: 34), PQQPYPQQPQQPFPQ (SEQ ID NO: 35), PQQSFPQQQPPFIQP (SEQ ID NO: 40), PQQPFPQPQQTFPQQ (SEQ ID NO: 43), and PFPQQPQQPFPQPQQ (SEQ ID NO: 44).

130. The kit of claim 128, wherein the one or more wheat peptides derived from gam comprise an amino acid sequence selected from the group consisting of QQQFPQPQQPQQQFL (SEQ ID NO: 33), QPQQPFPQQPQQPYP (SEQ ID NO: 34), PQQPFPQPQQTFPQQ (SEQ ID NO: 43), and PFPQQPQQPFPQPQQ (SEQ ID NO: 44).

131. The kit of claim 118, wherein the one or more wheat peptides derived from omg comprise an amino acid sequence selected from the group consisting of AMNIASASRLLSPRG (SEQ ID NO: 46), PRGKELHTPQEQFPQ (SEQ ID NO: 47), HTPQEQFPQQQQFPQ (SEQ ID NO: 48), PQQFPQQQQFPQQHQ (SEQ ID NO: 49), QQIPQQPQQFLQQQQ (SEQ ID NO: 50), FPQQQSPQQQQFPQQ (SEQ ID NO: 51), FPQQQEFPQQQFPQQ (SEQ ID NO: 52), QQFPRPQQSPEQQQF (SEQ ID NO: 53), PEQQQFPQQQFPQQP (SEQ ID NO: 54), QQSFSYQQQPFPQQP (SEQ ID NO: 55), QQQPFPQQPYPQQPY (SEQ ID NO: 56), QPQQPFPQQPQQPQQ (SEQ ID NO: 57), QPFPQQPQQPQQPFP (SEQ ID NO: 58),27527-0242WO1; ISMMS Ref.231101 PFPQPQQPFPWQPQQ (SEQ ID NO: 59), QFQESIKHKSKMKTF (SEQ ID NO: 60), QQRFPHTRQKFPRNP (SEQ ID NO: 61), STHHFPAQQPFPQQP (SEQ ID NO: 62), and PFPQQPGQIIPQQPQ (SEQ ID NO: 63).

132. The kit of claim 131, wherein the one or more wheat peptides derived from omg comprise an amino acid sequence selected from the group consisting of PQQFPQQQQFPQQHQ (SEQ ID NO: 49), FPQQQEFPQQQFPQQ (SEQ ID NO: 52), PEQQQFPQQQFPQQP (SEQ ID NO: 54), QQSFSYQQQPFPQQP (SEQ ID NO: 55), QQQPFPQQPYPQQPY (SEQ ID NO: 56), QPQQPFPQQPQQPQQ (SEQ ID NO: 57), PFPQPQQPFPWQPQQ (SEQ ID NO: 59), and STHHFPAQQPFPQQP (SEQ ID NO: 62).

133. The kit of claim 131, wherein the one or more wheat peptides derived from omg comprise an amino acid sequence selected from the group consisting of PQQFPQQQQFPQQHQ (SEQ ID NO: 49), FPQQQEFPQQQFPQQ (SEQ ID NO: 52), PEQQQFPQQQFPQQP (SEQ ID NO: 54), QQSFSYQQQPFPQQP (SEQ ID NO: 55), QQQPFPQQPYPQQPY (SEQ ID NO: 56), and QPQQPFPQQPQQPQQ (SEQ ID NO: 57).

134. The kit of claim 118, wherein the one or more wheat peptides derived from hmw comprise an amino acid sequence selected from the group consisting of SPQRPGQGQQPGQGQ (SEQ ID NO: 64), QGQQPGQGQQGQQPG (SEQ ID NO: 65), QQPGQGQQPGQLQQP (SEQ ID NO: 66), QQPAQGQQGQQPGQG (SEQ ID NO: 67), QLQQMIFWGIPALLR (SEQ ID NO: 68), ASPQQSGQGQQPGQE (SEQ ID NO: 69), GQGQQPGQEQQPGQG (SEQ ID NO: 70), QQPGQGQQDQQPGQR (SEQ ID NO: 71), QPGQKQQAGQGQQSG (SEQ ID NO: 72), QSGQGQQPGQGQPGY (SEQ ID NO: 73), QPGQGQQPGQGQQSG (SEQ ID NO: 74), SLRQPGQWQQPGQGQ (SEQ ID NO: 75), PQQSGQGQQLGQGQP (SEQ ID NO: 76), GQQPAQGQQSAQEQQ (SEQ ID NO: 77), PQQSGQGQQPGHEQQ (SEQ ID NO: 78), and EQQPGQWLQPGQGQQ (SEQ ID NO: 79).

135. The kit of claim 134, wherein the wheat peptide derived from hmw comprises an amino acid sequence QPGQGQQPGQGQQSG (SEQ ID NO: 74).27527-0242WO1; ISMMS Ref.231101 136. The kit of claim 118, wherein the one or more wheat peptides comprise an amino acid sequence selected from the group consisting of LSQQQQPPFSQQQPP (SEQ ID NO: 8), GQQQPFPPQQPYPQP (SEQ ID NO: 17), QPFPPQQSYPQPQPQ (SEQ ID NO: 20), LTILAMAITIGTANM (SEQ ID NO: 27), PFSQQPQQTFPQPQQ (SEQ ID NO: 30), FPQPQQTFPHQPQQQ (SEQ ID NO: 31), TFPHQPQQQFPQPQQ (SEQ ID NO: 32), QQQFPQPQQPQQQFL (SEQ ID NO: 33), QPQQPFPQQPQQPYP (SEQ ID NO: 34), PQQPYPQQPQQPFPQ (SEQ ID NO: 35), PQQSFPQQQPPFIQP (SEQ ID NO: 40), PQQPFPQPQQTFPQQ (SEQ ID NO: 43), PFPQQPQQPFPQPQQ (SEQ ID NO: 44), PQQFPQQQQFPQQHQ (SEQ ID NO: 49), FPQQQEFPQQQFPQQ (SEQ ID NO: 52), PEQQQFPQQQFPQQP (SEQ ID NO: 54), QQSFSYQQQPFPQQP (SEQ ID NO: 55), QQQPFPQQPYPQQPY (SEQ ID NO: 56), QPQQPFPQQPQQPQQ (SEQ ID NO: 57), PFPQPQQPFPWQPQQ (SEQ ID NO: 59), STHHFPAQQPFPQQP (SEQ ID NO: 62), and QPGQGQQPGQGQQSG (SEQ ID NO: 74).

137. The kit of claim 118, wherein the one or more wheat peptides comprise an amino acid sequence selected from the group consisting of LSQQQQPPFSQQQPP (SEQ ID NO: 8), GQQQPFPPQQPYPQP (SEQ ID NO: 17), QPFPPQQSYPQPQPQ (SEQ ID NO: 20), QQQFPQPQQPQQQFL (SEQ ID NO: 33), QPQQPFPQQPQQPYP (SEQ ID NO: 34), PQQPFPQPQQTFPQQ (SEQ ID NO: 43), PFPQQPQQPFPQPQQ (SEQ ID NO: 44), PQQFPQQQQFPQQHQ (SEQ ID NO: 49), FPQQQEFPQQQFPQQ (SEQ ID NO: 52), PEQQQFPQQQFPQQP (SEQ ID NO: 54), QQSFSYQQQPFPQQP (SEQ ID NO: 55), QQQPFPQQPYPQQPY (SEQ ID NO: 56), QPQQPFPQQPQQPQQ (SEQ ID NO: 57), and QPGQGQQPGQGQQSG (SEQ ID NO: 74).

138. The kit of any one of claims 118 to 121, wherein the one or more wheat peptides is derived from gamma gliadin (gam) and / or omega-5-gliadin (omg).

139. The kit of claim 138, wherein the one or more wheat peptides comprise an amino acid sequence selected from the group consisting of QQQFPQPQQPQQQFL (SEQ ID NO: 33), QPQQPFPQQPQQPYP (SEQ ID NO: 34), PQQPFPQPQQTFPQQ (SEQ ID NO: 43),27527-0242WO1; ISMMS Ref.231101 PFPQQPQQPFPQPQQ (SEQ ID NO: 44), PQQFPQQQQFPQQHQ (SEQ ID NO: 49), FPQQQEFPQQQFPQQ (SEQ ID NO: 52), PEQQQFPQQQFPQQP (SEQ ID NO: 54), QQSFSYQQQPFPQQP (SEQ ID NO: 55), QQQPFPQQPYPQQPY (SEQ ID NO: 56), and QPQQPFPQQPQQPQQ (SEQ ID NO: 57).

140. The kit of any one of claims 118 to 39, wherein each of the wheat peptides comprises a linker for coupling to the solid support.

141. The kit of claim 140, wherein the linker is -PEG12-biotin.

142. The kit of any one of claims 118 to 141, wherein the solid support is a microsphere bead, glass array, silicone array, membrane, or microtiter plate.

143. The kit of any one of claims 118 to 142 wherein the AAI is IgG and / or IgE.

144. The kit of claim 143, wherein the IgG is IgG4.

145. The kit of any one of claims 118 to 144, wherein the AAI-specific labeling reagent is a detectably labeled anti-human IgG antibody and / or a detectably labeled anti-human IgE antibody.

146. The kit of claim 145, wherein the detectable label is phycoerythrin, a fluorescent dye, horse radish peroxidase (HRP), or alkaline phosphatase.

Images